US12001939B2 - Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views - Google Patents
Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views Download PDFInfo
- Publication number
- US12001939B2 US12001939B2 US17/219,670 US202117219670A US12001939B2 US 12001939 B2 US12001939 B2 US 12001939B2 US 202117219670 A US202117219670 A US 202117219670A US 12001939 B2 US12001939 B2 US 12001939B2
- Authority
- US
- United States
- Prior art keywords
- echo
- images
- ultrasound device
- instructions
- view type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 238000002604 ultrasonography Methods 0.000 title claims abstract description 105
- 238000013473 artificial intelligence Methods 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 95
- 238000013528 artificial neural network Methods 0.000 claims abstract description 52
- 239000000523 sample Substances 0.000 claims abstract description 47
- 230000008569 process Effects 0.000 claims abstract description 40
- 210000002216 heart Anatomy 0.000 claims description 49
- 238000012545 processing Methods 0.000 claims description 36
- 238000004891 communication Methods 0.000 claims description 22
- 238000005259 measurement Methods 0.000 description 129
- 230000002861 ventricular Effects 0.000 description 94
- 230000000747 cardiac effect Effects 0.000 description 90
- 230000001746 atrial effect Effects 0.000 description 63
- 239000000090 biomarker Substances 0.000 description 61
- 238000010586 diagram Methods 0.000 description 59
- 230000003205 diastolic effect Effects 0.000 description 42
- 238000013527 convolutional neural network Methods 0.000 description 39
- 238000004364 calculation method Methods 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 26
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 description 24
- 210000005240 left ventricle Anatomy 0.000 description 24
- 238000012549 training Methods 0.000 description 23
- 230000008719 thickening Effects 0.000 description 22
- 238000003745 diagnosis Methods 0.000 description 21
- 238000010801 machine learning Methods 0.000 description 21
- 210000005242 cardiac chamber Anatomy 0.000 description 18
- 208000019622 heart disease Diseases 0.000 description 18
- 238000003384 imaging method Methods 0.000 description 14
- 101800001904 NT-proBNP Proteins 0.000 description 12
- 102400001263 NT-proBNP Human genes 0.000 description 12
- 210000001765 aortic valve Anatomy 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000002592 echocardiography Methods 0.000 description 11
- 238000004393 prognosis Methods 0.000 description 11
- 230000011218 segmentation Effects 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000012285 ultrasound imaging Methods 0.000 description 10
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 8
- 210000004115 mitral valve Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 210000003492 pulmonary vein Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000000591 tricuspid valve Anatomy 0.000 description 6
- 206010019280 Heart failures Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000003102 pulmonary valve Anatomy 0.000 description 5
- 210000002186 septum of brain Anatomy 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- 206010052337 Diastolic dysfunction Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 108020001621 Natriuretic Peptide Proteins 0.000 description 4
- 102000004571 Natriuretic peptide Human genes 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 239000000692 natriuretic peptide Substances 0.000 description 4
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 208000005228 Pericardial Effusion Diseases 0.000 description 3
- 241000465502 Tobacco latent virus Species 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 238000003709 image segmentation Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000001631 vena cava inferior Anatomy 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 2
- 102100035024 Carboxypeptidase B Human genes 0.000 description 2
- 206010007509 Cardiac amyloidosis Diseases 0.000 description 2
- 101000946524 Homo sapiens Carboxypeptidase B Proteins 0.000 description 2
- 241000890403 Ligustrum virus A Species 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000008253 Systolic Heart Failure Diseases 0.000 description 1
- 241001325280 Tricardia watsonii Species 0.000 description 1
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 1
- 206010044640 Tricuspid valve incompetence Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000013136 deep learning model Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001454 recorded image Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003291 sinus of valsalva Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/04—Architecture, e.g. interconnection topology
- G06N3/045—Combinations of networks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Clinical applications
- A61B8/0883—Clinical applications for diagnosis of the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/13—Tomography
- A61B8/14—Echo-tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/42—Details of probe positioning or probe attachment to the patient
- A61B8/4245—Details of probe positioning or probe attachment to the patient involving determining the position of the probe, e.g. with respect to an external reference frame or to the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/46—Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient
- A61B8/461—Displaying means of special interest
- A61B8/463—Displaying means of special interest characterised by displaying multiple images or images and diagnostic data on one display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/52—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/5292—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves using additional data, e.g. patient information, image labeling, acquisition parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/56—Details of data transmission or power supply
- A61B8/565—Details of data transmission or power supply involving data transmission via a network
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/06—Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons
- G06N3/063—Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using electronic means
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/08—Learning methods
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/40—ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/20—ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/488—Diagnostic techniques involving Doppler signals
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/04—Architecture, e.g. interconnection topology
- G06N3/047—Probabilistic or stochastic networks
Definitions
- Cardiovascular disease including heart failure is a major health problem accounting for about 30% of human deaths worldwide. Heart failure is also the leading cause of hospitalization in adults over the age of 65 years.
- Echocardiography is an important diagnostic aid in cardiology for the morphological and functional assessment of the heart.
- a clinician called a sonographer places an ultrasound device against the patient's chest to capture a number of 2D images/videos of the patients' heart. Reflected sound waves reveal the inner structure of the heart walls and the velocities of blood flows.
- the ultrasound device position is varied during an echo exam to capture different anatomical sections as 2D slices of the heart from different viewpoints or views.
- the clinician has the option of adding to these 2D images a waveform captured from various possible modalities including continuous wave Doppler, m-mode, pulsed wave Doppler and pulsed wave tissue Doppler.
- the 2D images/videos and Doppler modality images are typically saved in DICOM (Digital Imaging and Communications in Medicine) formatted files.
- DICOM Digital Imaging and Communications in Medicine
- the type of modality is partially indicated in the metadata of the DICOM file, the ultrasound device position in both the modality and 2D views, which is the final determinant of which cardiac structure has been imaged, is not.
- a clinician/technician goes through the DICOM files, manually annotates heart chambers and structures like the left ventricle (LV) and takes measurements of those structures. The process is reliant on the clinicians' training to recognize the view in each image and make the appropriate measurements.
- a cardiologist reviews the DICOM images and measurements, compares them to memorized guideline values and make a diagnosis based on the interpretation made from the echocardiogram.
- the current workflow process for analyzing DICOM images, measuring cardiac structures in the images and determining, predicting and prognosticating heart disease is highly manual, time-consuming and error-prone. Because the workflow process is so labor intensive, more than 95% of the images available in a typical patient echocardiographic study are never annotated or quantified.
- the view angle or Doppler modality type by which an image was captured is typically not labelled, which means the overwhelming majority of stored DICOMs from past patient studies and clinical trials do not possess the basic structure and necessary identification of labels to allow for machine learning on this data.
- the disclosed embodiments provide methods and systems for artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views.
- Aspects of exemplary embodiment include at least one processor receiving a plurality of the echo images captured by the ultrasound device, the ultrasound device including a display and a user interface (UI) that displays the echo images to a user, the echo images comprising 2D images and Doppler modality images of a heart.
- One or more neural networks process the echo images to continuously attempt to automatically classify the echo images by view type and generates corresponding classification confidence scores.
- the view type of the echo images are simultaneously displayed in the UI along with the echo images.
- Feedback indications are displayed in the UI of the ultrasound device to the user, where the feedback indications include which directions to move a probe of the ultrasound device so the probe can be placed in a correct position to capture and successfully classify the echo images.
- the disclosed embodiments provide an automated clinical workflow that diagnoses heart disease, while enhancing functionality of the mobile ultrasound device to improve the capture of echo image views.
- FIGS. 1 A- 1 C are diagrams illustrating embodiments of a system for implementing an automated clinical workflow diagnoses heart disease based on both cardiac biomarker measurements and AI recognition of 2D and Doppler modality Echocardiographic images for automated measurements and the diagnosis, prediction and prognosis of heart disease.
- FIG. 1 D illustrates a block diagram of an example point-of-care (POC) device for measuring cardiac biomarkers.
- POC point-of-care
- FIG. 2 illustrates architectural layers of the echo workflow engine.
- FIG. 3 is a flow diagram illustrating one embodiment of a process for performed by the echo workflow engine to diagnose heart disease based on both cardiac biomarker measurements and AI recognition of both 2D and Doppler modality echo images to perform automated measurements and the diagnosis, prediction and prognosis of heart disease.
- FIG. 4 A is a flow diagram illustrating details of the process for automatically recognizing and analyze both 2D and Doppler modality echo images to perform automated measurements and the diagnosis, prediction and prognosis of heart disease according to one embodiment.
- FIG. 4 B is a flow diagram illustrating advanced functions of the echo workflow engine.
- FIG. 5 A is diagram illustrating an example 2D echo image.
- FIG. 5 B is diagram illustrating an example Doppler modality image.
- FIGS. 6 A- 6 K are diagrams illustrating some example view types automatically classified by the echo workflow engine.
- FIG. 7 is a diagram illustrating an example 2D image segmented to produce annotations indicating cardiac chambers, and an example Doppler modality image segmented to produce a mask and trace waveform
- FIGS. 8 A and 8 B are diagrams illustrating examples of finding systolic/diastolic end points.
- FIGS. 9 A and 9 B are diagrams illustrating processing of an imaging window in a 2D echo image and the automated detection of out of sector annotations.
- FIGS. 10 A and 10 B are diagrams graphically illustrating structural measurements automatically generated from annotations of cardiac chambers in a 2D image, and velocity measurements automatically generated from annotations of waveforms in a Doppler modality.
- FIG. 11 is a diagram graphically illustrating measurements of global longitudinal strain that were automatically generated from the annotations of cardiac chambers in 2D images.
- FIG. 12 A is a diagram graphically illustrating an example set of best measurement data based on largest volume cardiac chambers and the saving of the best measurement data to a repository.
- FIG. 12 B is a diagram graphically illustrating the input of automatically derived measurements from a patient with normal LV EF measurements into a set of rules to determine a conclusion that the patient has normal diastolic function, diastolic dysfunction, or indeterminate.
- FIG. 13 is a diagram graphically illustrating the output of classification, annotation and measurement data to an example JSON file.
- FIG. 14 is a diagram illustrating a portion of an example report showing highlighting values that are outside the range of International guidelines.
- FIG. 15 is a diagram illustrating a portion of an example report of Main Findings that may be printed and/or displayed by the user.
- FIG. 16 A is a diagram showing a graph A plotting PCWP and HFpEF scores.
- FIG. 16 B is a diagram showing a graph B plotting CV mortality or hospitalization for HF.
- FIG. 17 is a diagram illustrating a federated training platform associated with the automated clinical workflow system.
- FIG. 18 is a diagram illustrating an automated clinical workflow system embodiment where the echo workflow engine is configured to provide a mobile ultrasound device with automatic recognition and measurements of 2D and Doppler modality Echocardiographic images.
- FIG. 19 is a flow diagram for enhancing an ultrasound device to perform AI recognition of echocardiogram images.
- FIG. 20 A is a diagram illustrating acquisition of echo images by the mobile ultrasound device.
- FIG. 20 B is a diagram of a user interface displayed by the mobile ultrasound device.
- FIGS. 20 C, 20 D and 20 E are diagrams illustrating example pages of a report showing calculated measurements of features in the echo images.
- FIG. 21 is a flow diagram showing processing by the echo workflow engine in a connected configuration comprising the echo workflow client in network communication with the echo workflow engine executing on one or more servers.
- FIG. 22 A is flow diagram illustrating an AI-based guidance process for an ultrasound device to improve capture of echo image views.
- FIG. 22 B is a diagram of a user interface displayed by the mobile ultrasound device.
- FIGS. 22 C- 22 E are diagrams showing a progression of feedback indications continuing from FIG. 22 B .
- the disclosed embodiments relate to artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views.
- AI artificial intelligence
- the following description is presented to enable one of ordinary skill in the art to make and use the invention and is provided in the context of a patent application and its requirements.
- Various modifications to the exemplary embodiments and the generic principles and features described herein will be readily apparent.
- the exemplary embodiments are mainly described in terms of particular methods and systems provided in particular implementations. However, the methods and systems will operate effectively in other implementations. Phrases such as “exemplary embodiment”, “one embodiment” and “another embodiment” may refer to the same or different embodiments.
- the embodiments will be described with respect to systems and/or devices having certain components.
- the systems and/or devices may include more or less components than those shown, and variations in the arrangement and type of the components may be made without departing from the scope of the invention.
- the exemplary embodiments will also be described in the context of particular methods having certain steps. However, the method and system operate effectively for other methods having different and/or additional steps and steps in different orders that are not inconsistent with the exemplary embodiments.
- the present invention is not intended to be limited to the embodiments shown, but is to be accorded the widest scope consistent with the principles and features described herein.
- the disclosed embodiments provide method and system for implementing a software-based automatic clinical workflow that diagnoses heart disease based on both cardiac biomarker measurements and AI recognition of 2D and Doppler modality echocardiographic images.
- the clinical workflow performs diagnosis, prediction and prognosis of heart disease, and can be deployed in workstation or mobile-based point-of-care systems.
- FIGS. 1 A- 1 C are diagrams illustrating embodiments of a system for implementing an automated clinical workflow diagnoses heart disease based on both cardiac biomarker measurements and AI recognition of 2D and Doppler modality Echocardiographic images.
- FIG. 1 A shows a basic standalone configuration for the automated clinical workflow system 10 A and a connected configuration 10 B.
- the automated clinical workflow 10 A is primarily implemented as a software application, referred to as echo workflow engine 12 , that executes on a computer 14 operating in a standalone setting, disconnected from other devices on network 26 .
- the computer 14 may be implemented in any form factor including a workstation, desktop, notebook, laptop server or tablet capable of running an operating system, such as Microsoft Windows® (e.g., Windows 7®, Windows 10®), Apple macOS®, Linux®, Apple iOS®, Android®, and the like.
- Microsoft Windows® e.g., Windows 7®, Windows 10®
- Apple macOS® e.g., Linux®, Apple iOS®, Android®, and the like.
- the computer 14 may include typical hardware components (not shown) including a processor, input devices (e.g., keyboard, pointing device, microphone for voice commands, buttons, touchscreen, etc.), output devices (e.g., a display device, speakers, and the like), and wired or wireless network communication interfaces (not shown) for communication.
- the computer 14 may include internal computer-readable media, such as memory (not shown) containing computer instructions comprising the echo workflow engine 12 , which implements the functionality disclosed herein when executed by one or more computer processors.
- the computer 14 may further include local internal storage for storing one or more databases 16 and an image file archive 18 .
- the contents of the image file archive 18 include echocardiogram image files (also referred to herein as echo images), which in some embodiments may be stored in DICOM (Digital Imaging and Communications in Medicine) format.
- DICOM Digital Imaging and Communications in Medicine
- the computer 14 is in communication with peripheral devices such a point-of-care (POC) device 25 , an ultrasound imaging device 24 , or both.
- POC device 25 is capable of measuring cardiac biomarkers in POC environments such as an emergency room, intensive care unit, physician's office, an ambulance, a patient setting, and remote emergency sites, as explained below with reference with FIG. 1 D .
- the ultrasound imaging device 24 captures echocardiogram images of a patient's organ (e.g., a heart), which may then be stored as a patient study using the database 16 and image file archive 18 .
- the computer 14 may be located in a hospital or clinical lab environment where Echocardiography is performed as a diagnostic aid in cardiology for the morphological and functional assessment of the heart.
- Echocardiography is performed as a diagnostic aid in cardiology for the morphological and functional assessment of the heart.
- a sonographer or technician places the ultrasound imaging device 24 against the patient's chest to capture 2D echo images/videos of the heart to help diagnose the particular heart ailment.
- Measurements of the structure and blood flows are typically made using 2D slices of the heart and the position of the ultrasound imaging device 24 is varied during an echo exam to capture different anatomical sections of the heart from different viewpoints.
- the technician has the option of adding to these 2D echo images a waveform captured from various possible modalities including: continuous wave Doppler, m-mode, pulsed wave Doppler and pulsed wave tissue Doppler.
- the 2D images and Doppler waveform images may be saved as DICOM files. Although the type of modality is sometimes indicated in the metadata of the DICOM file, the 2D view is not.
- the computer 14 may further include removable storage devices such as an optical disk 20 and/or a flash memory 22 and the like for storage of the echo images.
- the removable storage devices may be used as an import source of echo images and related data structures into the internal image file archive 18 , rather than or in addition to, the ultrasound imaging device 24 .
- the removable storage devices may also be used as an archive for echocardiogram data stored in the database 16 and/or the image file archive 18 .
- FIG. 1 A also shows an advanced optional embodiment, referred to as connected configuration 10 B, where the computer 14 may be connected through the network 26 and a router 28 to other DICOM based devices, such as DICOM servers 30 , network file share devices 32 , echo workstations 34 , and/or cloud storage services 36 hosting DICOM files.
- the servers 30 are also computers comprising a processor, input and output devices, wired or wireless network communication interfaces for communication, and computer-readable media, such as memory containing computer instructions comprising components of the echo workflow engine 12 .
- the connected configuration 10 B several possible interactions with the database 16 and the image file archive 18 are possible, as described below.
- One possible interaction is to use the cloud storage services 36 as an internal archive.
- the computer 14 may not have sufficient storage to host all files and the echo workflow engine 12 may be configured to use external network storage of the cloud storage services 36 for file storage.
- Another possible interaction is to use the cloud storage services 36 as an import source by i) selecting a DICOM file set or patient study, which includes the DICOM and Doppler waveforms images and patient data and examination information, including cardiac biomarker measurements.
- the patient study may also be selected by a reserved DICOMDIR file instance, from which the patient, exams and image files are read.
- DICOM servers 30 acting as DICOM servers (workstations with modalities CFind, CMove and CStore) in order to retrieve patients, exams and images by performing a CFind operation, followed by a CMove operation, to request the remote device to send the cardiac biomarker measurements and/or images resulting from the CFind operation.
- DICOM servers workstations with modalities CFind, CMove and CStore
- the computer 14 of FIG. 1 A is implemented as a handheld device 14 ′, such as a tablet or a mobile phone, connected to a wired or wireless portable ultrasound scanner probe 24 ′ that transmits echo images to the handheld device 14 ′.
- the echo workflow engine 12 may be implemented as an application executed by the handheld device 14 ′.
- the handheld device 14 ′ may transmit the echo images to another computer/server executing the echo workflow engine 12 for processing.
- FIG. 1 C illustrates a software as a service (SaaS) configuration 10 D for the automated clinical workflow.
- the echo workflow engine 12 is run on a server 40 that is in communication over the network 26 with a plurality of client devices 42 .
- the server 40 and the echo workflow engine 12 may be part of a third-party service that provides automated measurements and the diagnosis, prediction and prognosis of heart disease to client devices (e.g., hospital, clinic, or doctor computers) over the Internet.
- client devices e.g., hospital, clinic, or doctor computers
- server 40 is shown as a single computer, it should be understood that the functions of server 40 may be distributed over more than one server.
- 1 C may be implemented as a virtual entity whose functions are distributed over multiple client devices 42 .
- the echo workflow engine 12 is shown as a single component in each embodiment, the functionality of the echo workflow engine 12 may be separated into a greater number of modules/components.
- the echo workflow engine 12 mimics the standard clinical practice of diagnosing heart disease of a patient by combining cardiac biomarker measurements and processing DICOM files of the patient using a combination of machine learning, image processing, and DICOM workflow techniques to derive clinical measurements, diagnose specific diseases, and prognosticate patient outcomes, as described below. While an automated solution to echo image interpretation using machine learning has been previously proposed, the solution fails to take cardiac biomarker measurements into account and only analyzes 2D echo images and not Doppler modality waveform images. The solution also mentions disease prediction, but only attempts to handle two diseases (hypertrophic cardiomyopathy and cardiac amyloidosis) and the control only compares normal patients to diseased patients.
- the echo workflow engine 12 of the disclosed embodiments improves on the automated solution by optionally combining cardiac biomarker measurements with machine learning that automatically recognizes and analyzes not only 2D echo images but also Doppler modality waveform images in order to diagnose heart disease.
- the echo workflow engine 12 is also capable of comparing patients having similar-looking heart diseases (rather than comparing normal patients to diseased patients), and automatically identifies additional diseases, including both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
- HFrEF heart failure due to left ventricular systolic dysfunction or systolic heart failure and occurs when the ejection fraction is less than 40%.
- HFpEF is a form of congestive heart failure where in the amount of blood pumped from the heart's left ventricle with each beat (ejection fraction) is greater than 50%.
- the echo workflow engine 12 automatically takes into account cardiac biomarker measurements.
- Cardiac biomarkers are substances that are released into the blood when the heart is damaged or stressed. Measurements of these biomarkers are used to help diagnose acute coronary syndrome (ACS) and cardiac ischemia, conditions associated with insufficient blood flow to the heart. Tests for cardiac biomarkers can also be used to help determine a person's risk of having these conditions. Increases in one or more cardiac biomarkers in the blood can identify people with ACS or cardiac ischemia, allowing rapid and accurate diagnosis and appropriate treatment of their condition.
- ACS acute coronary syndrome
- cardiac ischemia conditions associated with insufficient blood flow to the heart.
- Tests for cardiac biomarkers can also be used to help determine a person's risk of having these conditions. Increases in one or more cardiac biomarkers in the blood can identify people with ACS or cardiac ischemia, allowing rapid and accurate diagnosis and appropriate treatment of their condition.
- Example types of cardiac biomarkers include B-type natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP), High-sensitivity C-reactive Protein (hs-CRP), Cardiac Troponin, Creatine Kinase (CK), Creatine kinase-MB (CK-MB), and Myoglobin.
- BNP B-type natriuretic peptide
- NT-proBNP N-terminal pro-brain natriuretic peptide
- hs-CRP High-sensitivity C-reactive Protein
- Cardiac Troponin Creatine Kinase
- CK-MB Creatine kinase-MB
- Myoglobin Cardiac biomarker tests are typically available to a health practitioner 24 hours a day, 7 days a week with a rapid turn-around-time. Some of the tests are performed at the point of care (POC), e.g
- NP plasma natriuretic peptide
- NT-proBNP N-terminal pro-brain natriuretic peptide
- Echocardiography is needed to distinguish among the types of HF (HFpEF or HF with reduced ejection fraction [HFrEF])—a distinction that cannot be made by raised NP levels alone and is critical for the selection of appropriate therapies.
- Traditional echocardiography is highly manual, time consuming, error-prone, limited to specialists, and involves long waiting times (e.g. up to 9 months in some areas of NHS Scotland).
- AI Artificial Intelligence
- Such AI-enabled echocardiographic interpretation therefore not only increases efficiency and accuracy, but also opens the door to decision support for non-specialists.
- a combination of circulating cardiac and echocardiographic biomarkers represents an ideal diagnostic panel for HF.
- Such combined interpretation of multimodal data was not possible in the past since blood-based and imaging-based labs largely functioned independent of each other.
- PACS picture archiving and communication system
- the development of true “companion diagnostics” with combined interpretation of both blood and imaging biomarkers is possible.
- advancements in medical AI enable deep learning models to be developed for greater diagnostic/predictive precision than ever achieved before. Automation of these algorithms, built into decision support tools for clinical application, has the potential to transform the diagnosis of HF.
- FIG. 1 D illustrates a block diagram of an example point-of-care (POC) device for measuring cardiac biomarkers.
- the POC device 42 A is capable of measuring cardiac biomarkers in POC environments such as an emergency room, intensive care unit, physician's office, an ambulance, a patient setting, and remote emergency sites.
- a patient blood sample may be delivered to the POC device 42 A either through a strip reader 50 that receives an insert strip (not shown) containing the sample, or through a sample reader 52 that receives the sample from a syringe or a patient's finger.
- the POC device 42 A analyzes the blood sample for one or more cardiac biomarkers and displays the results on a display 54 within minutes.
- the POC device 42 A can store the results as well as wirelessly transmit the results to other systems/devices in the POC system, such as the echo workflow engine 12 , and/or the results can be saved in the patient record or study.
- the POC device 42 A measures at least B-type natriuretic peptide (BNP) and/or N-terminal pro-brain natriuretic peptide (NT-proBNP), as shown. In one embodiment, the POC device 42 A may measure only NT-proBNP. In another embodiment, the POC device 42 A may also measure other cardiac biomarkers including High-sensitivity C-reactive Protein (hs-CRP), Cardiac Troponin, Creatine Kinase (CK), Creatine kinase-MB (CK-MB), and Myoglobin. In one specific embodiment, an example of the POC device 42 A is the commercially available COBAS 232 POC SystemTM by ROCHE.
- hs-CRP High-sensitivity C-reactive Protein
- CK Creatine Kinase
- CK-MB Creatine kinase-MB
- Myoglobin Myoglobin.
- an example of the POC device 42 A is the commercially available COBAS
- FIG. 2 illustrates architectural layers of the echo workflow engine 12 .
- the echo workflow engine 12 may include a number of software components such as software servers or services that are packaged together in one software application.
- the echo workflow engine 12 may include a machine learning layer 200 , a presentation layer 202 , and a database layer 204 .
- the machine learning layer 200 comprises several neural networks to process incoming echo images and corresponding metadata.
- the neural networks used in the machine learning layer may comprise a mixture of different classes or model types.
- machine learning layer 200 utilizes a first neural network to classify 2D images by view type, and uses a second set of neural networks 200 B to both extract features from Doppler modality images and to use the extracted features to classify the Doppler modality images by region (the neural networks used to extract features may be different than the neural network used to classify the images).
- the first neural network 200 A and the second set of neural networks 200 B may be implemented using convolutional neural network (CNN) and may be referred to as classification neural networks or CNNs.
- CNN convolutional neural network
- a third set of neural networks 2000 including adversarial networks, are employed for each classified 2D view type in order to segment the cardiac chambers in the 2D images and produce segmented 2D images.
- a fourth set of neural networks 200 D are used for each classified Doppler modality region in order to segment the Doppler modality images to generate waveform traces.
- the machine learning layer 200 may further include a set of one or more prediction CNNs for disease prediction and optionally a set of one or more prognosis CNNs for disease prognosis (not shown).
- the third and fourth sets of neural networks 2000 and 200 D may be implemented using CNNs and may be referred to as segmentation neural networks or CNNs.
- a CNN is a class of deep, feed-forward artificial neural network typically use for analyzing visual imagery.
- Each CNN comprises an input and an output layer, as well as multiple hidden layers.
- each node or neuron receives an input from some number of locations in the previous layer.
- Each neuron computes an output value by applying some function to the input values coming from the previous layer.
- the function that is applied to the input values is specified by a vector of weights and a bias (typically real numbers). Learning in a neural network progresses by making incremental adjustments to the biases and weights.
- the vector of weights and the bias are called a filter and represents some feature of the input (e.g., a particular shape).
- the machine learning layer 200 operates in a training mode to train each of the CNNs 200 A- 200 D prior to the echo workflow engine 12 being placed in an analysis mode to automatically recognize and analyze echo images in patient studies.
- the CNNs 200 A- 200 D may be trained to recognize and segment the various echo image views using thousands of echo images from an online public or private echocardiogram DICOM database.
- the presentation layer 202 is used to format and present information to a user.
- the presentation layer is written in HTML 5, Angular 4 and/or JavaScript.
- the presentation layer 202 may include a Windows Presentation Foundation (WPF) graphical subsystem 202 A for implementing a light weight browser-based user interface that displays reports and allows a user (e.g., doctor/technician) to edit the reports.
- WPF Windows Presentation Foundation
- the presentation layer 202 may also include an image viewer 202 B (e.g., a DICOM viewer) for viewing echo images, and a python server 202 C for running the CNN algorithms and generating a file of the results in JavaScript Object Notation (JSON) format, for example.
- JSON JavaScript Object Notation
- the database layer 204 in one embodiment comprises a SQL database 204 A and other external services that the system may use.
- the SQL database 204 A stores patient study information for individual patient studies, including cardiac biomarker measurements input to the system.
- the database layer 204 may also include the image file archive 18 of FIG. 1 A .
- FIG. 3 is a flow diagram illustrating one embodiment of a process for performed by the echo workflow engine 12 to diagnose heart disease based on both cardiac biomarker measurements and AI recognition of both 2D and Doppler modality echo images to perform automated measurements. The process occurs once the echo workflow engine 12 is trained and placed in analysis mode.
- the process may begin by the echo workflow engine 12 receiving from a memory one or more patient studies comprising i) one or more cardiac biomarker measurements derived from a patient sample, and ii) a plurality of echocardiogram images taken by an ultrasound device of a patient organ, such as a heart (block 300 ).
- the cardiac biomarker measurements may be obtained directly from a local or remote source, including from a handheld point-of-care (POC) device, such as the POC device 42 A shown in FIG. 1 D .
- the cardiac biomarker measurements may be obtained through traditional lab test.
- the cardiac biomarker measurements may be stored in a patient study and/or an archive, such as in an electronic medical record system (EMR) record and the like.
- EMR electronic medical record system
- the patient study may include 70-90 images and videos.
- a first module of the echo workflow engine 12 may be used to operate as a filter to separate the plurality of echocardiogram images according to 2D images and Doppler modality images based on analyzing image metadata (block 302 ).
- the first module analyzes the DICOM tags, or metadata, incorporated in the image, and runs an algorithm based upon the tag information to distinguish between 2D and modality images, and then separate the modality images into either pulse wave, continuous wave, PWTDI or m-mode groupings.
- a second module of the echo workflow engine 12 may perform color flow analysis on extracted pixel data using a combination of analyzing both DICOM tags/metadata and color content within the images, to separate views that contain color from those that do not.
- a third module then anonymizes the data by removing metatags that contain personal information and cropping the images to exclude any identifying information.
- a fourth module then extracts the pixel data from the images and converts the pixel data to numpy arrays for further processing.
- one or more of neural networks are used classify the echo images by view type.
- a first neural network is used by the echo workflow engine 12 to classify the 2D images by view type (block 304 ); and a second set of neural networks is used by the echo workflow engine 12 to extract the features from Doppler modality images and to use the extracted features to classify the Doppler modality images by region (block 306 ).
- the processing of 2D images is separate from the processing of Doppler modality images.
- the first neural network and the second set of neural networks may implemented using the set of classification convolutional neural networks (CNNs) 200 A.
- CNNs classification convolutional neural networks
- a five class CNN may be used to classify the 2D images by view type and an 11 class CNN may be used to classify the Doppler modality images by region.
- a plurality of each of type of neural network can be implemented and configured to use a majority voting scheme to determine the optimal answer. For example a video can be divided into still image frames, and each frame may be given a classification label, i.e., of a vote, and the classification label receiving the most votes is applied to classify the video.
- the echo workflow engine 12 is trained to classify many different view types.
- the echo workflow engine 12 may classify at least 11 different view types including parasternal long axis (PLAX), apical 2-, 3-, and 4-chamber (A2C, A3C, and A4C), A4C plus pulse wave of the mitral valve, A4C plus pulse wave tissue Doppler on the septal side, A4C plus pulse wave tissue Doppler on the lateral side, A4C plus pulse wave tissue Doppler on the tricuspid side, A5C plus continuous wave of the aortic valve, A4C+Mmode (TrV), A5C+PW (LVOT).
- PPAX parasternal long axis
- A4C apical 2-, 3-, and 4-chamber
- A4C plus pulse wave of the mitral valve A4C plus pulse wave tissue Doppler on the septal side
- A4C plus pulse wave tissue Doppler on the lateral side A4C plus pulse wave tissue Doppler on the
- a third set of neural networks is used by the echo workflow engine 12 to segment regions of interest (e.g., cardiac chambers) in the 2D images to produce annotated or segmented 2D images (block 308 ).
- a fourth set of neural networks is used by the echo workflow engine 12 for each classified Doppler modality region to generate waveform traces and to generate annotated or segmented Doppler modality images (block 309 ).
- the process of segmentation includes determining locations where each of the cardiac chambers begin and end to generate outlines of structures of the heart (e.g., cardiac chambers) depicted in each image and/or video. Segmentation can also be used to trace the outline of the waveform depicting the velocity of blood flow in a Doppler modality.
- the third and fourth sets of neural networks maybe referred to as segmentation neural networks and my comprise the set of segmentation CNNs 200 B and 2000 .
- the choice of segmentation CNN used is determined by the view type of the image, which makes the prior correct classification of view type a crucial step.
- a separate neural network can be used to smooth outlines of the segmentations.
- segmentation CNNs may be trained from hand-labeled real images or artificial images generated by general adversarial networks (GANs).
- GANs general adversarial networks
- the echo workflow engine 12 calculates for the patient study, measurements of cardiac features for both left and right sides of the heart (block 310 ).
- the echo workflow engine 12 then generates conclusions by comparing the one or more cardiac biomarker measurements and calculated measurements of cardiac features with International cardiac guidelines (block 312 ).
- the echo workflow engine 12 further outputs at least one report to a user showing ones of the one or more cardiac biomarker measurements and the calculated measurements that fall within or outside of the International cardiac guidelines (block 314 ).
- two reports are generated and output: the first report is a list of the cardiac biomarker measurements and the calculated values for each measurement with the highest confidence as determined by a rules based engine, highlighting values among the measurements that fall outside of the International guidelines; and the second report is a comprehensive list of all cardiac biomarker measurements and echo image measurements calculated on every image frame of every video, in every view, generating large volumes of data.
- All report data and extracted pixel data may be stored in a structured database to enable machine learning and predictive analytics on images that previously lacked the quantification and labelling necessary for such analysis.
- the structured database may be exported to a cloud based server or may remain on premises (e.g., of the lab owning the images) and can be connected to remotely. By connecting these data sources into a single network, disease prediction algorithms can be progressively trained across multiple network nodes, and validated in distinct patient cohorts.
- the reports may be electronically displayed to a doctor and/or a patient on a display of an electronic device and/or as a paper report.
- the electronic reports may be editable by the user per rule or role based permissions, e.g., a cardiologist may be allowed to modify the report, but a patient may have only view privileges.
- FIG. 4 A is a flow diagram illustrating further details of the process for automatically recognizing and analyze both 2D and Doppler modality echo images to perform automated measurements and the diagnosis, prediction and prognosis of heart disease according to one embodiment.
- the process may begin with receiving one or more patient studies ( FIG. 3 block 300 ), which comprises blocks 400 - 4010 .
- echo images from each of the patient studies are automatically downloaded into the image file archive 18 (block 400 ).
- the cardiac biomarker measurements and the echo images may be received from a local or remote storage source of the computer 14 .
- the local storage sources may include internal/external storage of the computer 14 including removable storage devices.
- the remote storage sources may include the ultrasound imaging device 24 , the POS device 25 , the DICOM servers 30 , the network file share devices 32 , the echo workstations 34 , and/or the cloud storage services 36 (see FIG. 1 ).
- the echo workflow engine 12 includes functions for operating as a picture archiving and communication server (PACS), which is capable of handling images from multiple modalities (source machine types, one of which is the ultrasound imaging device 24 ).
- PACS picture archiving and communication server
- the echo workflow engine 12 uses PACS to download and store the echo images into the image file archive 18 and provides the echo workflow engine 12 with access to the echo images during the automated workflow.
- the format for PACS image storage and transfer is DICOM (Digital Imaging and Communications in Medicine).
- Non-image patient data may include metadata embedded within the DICOM images and/or scanned documents, which may be incorporated using consumer industry standard formats such as PDF (Portable Document Format), once encapsulated in DICOM.
- received patient studies are placed in a processing queue for future processing, and during the processing of each patient study, the echo workflow engine 12 queues and checks for unprocessed echo images (block 404 ).
- the echo workflow engine 12 monitors the status of patient studies, and keeps track of them in a queue to determine which have been processed and which are still pending.
- prioritization of the patient studies in the queue may be configured by a user. For example, the patient studies may be prioritized in the queue for processing according to the date of the echo exam, the time of receipt of the patient study or by estimated severity of the patient's heart disease.
- any unprocessed echo images are then filtered for having a valid DICOM image format and non DICOM files in an echo study are discarded (block 406 ).
- the echo images are filtered for having a particular type of format, for example, a valid DICOM file format, and any other file formats may be ignored. Filtering the echo images for having a valid image file format enhances the reliability of the echo workflow engine 12 by rejecting invalid DICOM images for processing.
- Any unprocessed valid echo images are then opened and processed in the memory of the computer 14 (block 408 ). Opening of the echo images for the patient study in memory of the computer 14 is done to enhance processing speed by echo workflow engine 12 . This is in contrast to an approach of opening the echo files as sub-processes, saving the echo files to disk, and then reopening each echo image during processing, which could significantly slow processing speed.
- the echo workflow engine 12 then extracts and stores the metadata from the echo images and then anonymizes the images by blacking out the images and overwriting the metadata in order to protect patient data privacy by covering personal information written on the image (block 410 ).
- DICOM formatted image files include metadata referred to as DICOM tags that may be used to store a wide variety of information such as patient information, Doctor information, ultrasound manufacture information, study information, and so on.
- the extracted metadata may be stored in the database 16 and the metadata in image files is over written for privacy.
- the echo workflow engine 12 separates 2D images from Doppler modality images so the two different image types can be processed by different pipeline flows, described below.
- the separating of the images may comprise blocks 412 - 414 .
- the 2D images are separated from the Doppler modality images by analyzing the metadata (block 412 ).
- FIGS. 5 A and 5 B are diagrams illustrating an example 2D echo image 500 and an example Doppler modality image 502 including a waveform, respectively.
- the echo workflow engine 12 may determine the image type by examining metadata/DICOM tags.
- information within the DICOM tags may be extracted in order to group the images into one of the following four classes: 2D only, pulsed-wave (PW), continuous wave (CW), and m-mode.
- the transducer frequency of the ultrasound imaging device 24 in the metadata may be used to further separate some of the PW images into a fifth class: pulsed-wave tissue doppler imaging (PWTDI).
- PWTDI pulsed-wave tissue doppler imaging
- the echo workflow engine 12 may also filter out images with a zoomed view, which may also be determined by analyzing the metadata (block 414 ). Any of the echo images that has been zoomed during image capture are not processed through the pipeline because when zooming, useful information is necessarily left out of the image, meaning the original image would have to be referenced for the missing data, which is a duplication of effort that slows processing speed. Accordingly, rather than potentially slowing the process in such a manner, the echo workflow engine 12 filters out or discards the zoomed images to save processing time. In an alternative embodiment, filtering out zoomed images in block 414 may be performed prior to separating the images in block 412 .
- the echo workflow engine 12 extracts and converts the image data from each echo image into numerical arrays 416 (block 416 ).
- the pixel data comprises a series of image frames played in sequence to create a video. Because the image frames are unlabeled, the view angle needs to be determined.
- the Doppler modality images that include waveform modalities there are two images in the DICOM file that may be used for subsequent view identification, a waveform image and an echo image of the heart.
- the pixel data is extracted from the DICOM file and tags in the DICOM file determine the coordinates to crop the images.
- the cropped pixel data is stored in numerical arrays for further processing.
- blocks 412 , 414 and 416 may correspond to the separating images block 302 of FIG. 3 .
- the echo workflow engine 12 After separating images, the echo workflow engine 12 attempts to classify each of the echo images by view type.
- view classification FIG. 3 blocks 304 and 306 ) correspond to blocks 418 - 422 .
- the echo workflow engine 12 attempts to classify each of the echo images by view type by utilizing parallel pipeline flows.
- the parallel pipeline includes a 2D image pipeline and a Doppler modality image pipeline.
- the 2D pipeline flow begins by classifying, by a first CNN, the 2D images by view type (block 418 ), corresponding to block 304 from FIG. 3 .
- the Doppler modality image pipeline flow begins by classifying, by a second CNN, the Doppler modality images by view type (block 420 ), corresponding to block 306 from FIG. 3 .
- FIGS. 6 A- 6 K are diagrams illustrating some example view types automatically classified by the echo workflow engine 12 .
- example view types may include parasternal long axis (PLAX), apical 2-, 3-, and 4-chamber (A2C, A3C, and A4C), A4C plus pulse wave of the mitral valve, A4C plus pulse wave tissue Doppler on the septal side, A4C plus pulse wave tissue Doppler on the lateral side, A4C plus pulse wave tissue Doppler on the tricuspid side, A5C plus continuous wave of the aortic valve, A4C+Mmode (TrV), A5C+PW (LVOT).
- PPAX parasternal long axis
- A4C apical 2-, 3-, and 4-chamber
- A4C plus pulse wave of the mitral valve A4C plus pulse wave tissue Doppler on the septal side
- A4C plus pulse wave tissue Doppler on the lateral side A4C plus pulse wave tissue Doppler on
- 2D image classification is performed as follows. If the DICOM file contains video frames from a 2D view, only a small subset of the video frames are analyzed to determine 2D view classification for more efficient processing.
- the subset of the video frames may range approximately 8-12 video frames, but preferably 10 frames are input into one of the CNNs 200 A trained for 2D to determine the actual view.
- subset a video frames may be randomly selected from the video file.
- the CNNs 200 A classify each of the analyzed video frames as one of: A2C, A3C, A4C, A5C, PLAX Modified, PLAX, PSAX AoV level, PSAX Mid-level, Subcostal Ao, Subcostal Hep vein, Subcostal IVC, Subcostal LAX, Subcostal SAX, Suprasternal and Other.
- Doppler modality images comprise two images, an echocardiogram image of the heart and a corresponding waveform, both of which are extracted from the echo file for image processing.
- Doppler modality image classification of continuous wave (CW), pulsed-wave (PW), and M-mode images is performed as follows.
- the two extracted images are input to one of the CNNs 200 A trained for CW, PW, PWTDI and M-mode view classification to further classify the echo images as one of: CW (AoV), CW (TrV), CW Other, PW (LVOT), PW (MV), PW Other, PWTDI (lateral), PWTDI (septal), PWTDI (tricuspid), M-mode (TrV) and M-mode Other.
- Customization of the CNNs 200 A occurs in the desired number of layers used and the quantity of filters within each layer.
- the correct size of the CNNs may be determined through repeated training and adjustments until optimal performance levels are reached.
- the echo workflow engine 12 maintains classification confidence scores that indicate a confidence level that the view classifications are correct.
- the echo workflow engine 12 filters out the echo images having classification confidence scores that fail to meet a threshold, i.e., low classification confidence scores (block 422 ).
- Multiple algorithms may be employed to derive classification confidence scores depending upon the view in question. Anomalies detected in cardiac structure annotations, image quality, cardiac cycles detected and the presence of image artifacts may all serve to decrease the classification confidence score and discard an echo image out of the automated echo workflow.
- the echo workflow engine 12 generates and analyzes several different types of confidence scores at different stages of processing, including classification, annotation, and measurements (e.g., blocks 422 , 434 and 442 ). For example, poor quality annotations or classifications, which may be due to substandard image quality, are filtered out by filtering the classification confidence scores. In another example, in a patient study the same view may be acquired more than once, in which case the best measurements are chosen by filtering out low measurement confidence scores as described further below in block 442 . Any data having a confidence score that meets a predetermined threshold continues through the workflow. Should there be a duplication of measurements both with high confidence, the most clinically relevant measurement may be chosen.
- the echo workflow engine 12 performs image segmentation to define regions of interest (ROI).
- ROI regions of interest
- image segmentation is the process of partitioning a digital image into multiple segments (sets of pixels) to locate and boundaries (lines, curves, and the like) of objects.
- annotations are a series of boundary lines overlaying overlaid on the image to highlight segment boundaries/edges.
- the segmentation to define ROI corresponds to blocks 426 - 436 .
- the 2D image pipeline annotates, by a third CNN, regions of interests, such as cardiac chambers in the 2D images, to produce annotated 2D images (block 426 ).
- An annotation post process then erodes the annotations to reduce their dimensions, spline fits outlines of cardiac structures and adjusts locations of the boundary lines closer to the region of interest (ROIs) (block 427 ).
- the 2D image pipeline continues with analyzing the ROIs (e.g., cardiac chambers) in the annotated 2D images to estimate volumes and determine key points in the cardiac cycle by finding systolic/diastolic end points (block 430 ).
- measurements are taken at the systolic or diastolic phase of the cardiac cycle, i.e. when the left ventricle reaches the smallest volume (systole) or the largest volume (diastole). From the 2D video images, it must be determined which end points are systolic and which are diastolic based on the size of the estimated volumes of the left ventricle. For example a significantly large left ventricle may indicate a dystonic end point, while a significantly small volume may indicate a systolic end point. Every video frame is annotated and the volume of the left ventricle is calculated throughout the whole cardiac cycle. The frames with minimum and maximum volumes are detected with a peak detection algorithm.
- the Doppler modality pipeline analyzes the Doppler modality images and generates, by a fourth CNN, a mask and a waveform trace in the Doppler modality images to produce annotated Doppler modality images (block 431 ).
- FIG. 7 is a diagram illustrating an example 2D image segmented in block 426 to produce annotations 700 indicating cardiac chambers, and an example Doppler modality image segmented in block 431 to produce a mask and waveform trace 702 .
- the third and fourth CNNs may correspond to segmentation CNNs 200 B.
- each of the CNNs 200 B used to segment the 2D images and Doppler modality images may be implemented as U-Net CNN, which is convolutional neural network developed for biomedical image segmentation. Multiple U-Nets may be used. For example, for 2D images, a first U-Net CNN can be trained to annotate ventricles and atria of the heart from the A2C, A3C, A4C views. A second U-net CNN can be trained to annotate the chambers in the PLAX views.
- a third U-Net CNN can be trained to segment the waveform, remove small pieces of the segments to find likely candidates for the region of interest, and then reconnect the segments to provide a full trace of the movement of the mitral valve.
- a fourth U-net CNN can be trained to annotate and trace blood flow.
- a fifth U-net CNN trained to annotate and trace the blood flow.
- a sixth U-net CNN can be trained to annotate and trace movement of the tissues structures (lateral/septal/tricuspid valve).
- the Doppler modality pipeline continues by processing the annotated Doppler modality images with a sliding window to identify cycles, peaks are measured in the cycles, and key points in the cardiac cycle are determined by finding systolic/diastolic end points (block 432 ).
- a Doppler modality video may capture three heart cycles and the sliding window is adjusted in size to block out two of the cycles so that only one selected cycle is analyzed. Within the selected cycle, the sliding window is used to identify cycles, peaks are measured in the cycles, and key points in the cardiac cycle are determined by finding systolic/diastolic end points.
- FIGS. 8 A and 8 B are diagrams illustrating examples of finding systolic/diastolic end points in the cardiac cycle, for both 2D and Doppler modalities, respectively, which are key points in order to take accurate cardiac measurements.
- the echo workflow engine 12 maintains annotation confidence scores corresponding to the estimated volumes, systolic/diastolic end points, identified cycles and measured peaks.
- the echo workflow engine 12 filters out annotated images having annotation confidence scores that fail to meet a threshold, i.e., low annotated confidence scores (block 434 ).
- Examples of low confidence annotations may include annotated images having one or more of: excessively small areas/volumes, sudden width changes, out of proportion sectors, partial heart cycles, and insufficient heart cycles.
- the echo workflow engine 12 defines an imaging window for each image, and filters out annotations that lie outside of the imaging window (block 435 ).
- FIGS. 9 A and 9 B are diagrams illustrating processing of an imaging window in a 2D echo image 900 .
- a shaded ROI 902 is shown having unshaded regions or holes 904 therein.
- Open CV morphology transformations are used to fill the holes 904 inside the ROI, as shown in FIG. 9 B .
- a Hough line transformation may be used to find an imaging window border 906 .
- a Hough transform is a feature extraction technique used in digital image processing to find imperfect instances of objects within a certain class of shapes.
- Annotations 908 with a significant number of pixels outside the border of the imaging window are then discarded.
- the patient studies may not include Doppler modality images.
- the disclosed embodiments accommodate for such handheld configurations by using the 2D images to simulate Doppler modality measurements by using Left Ventricular (LV) and Left Atrial (LA) volume measurements to derive E, e′ and A (e.g., early and late diastolic transmittal flow and early/mean diastolic tissue velocity) measurements (block 436 ).
- simulating the Doppler modality measurements may be optional and may be invoked based on a software setting indicating the presence of a handheld configuration and/or absence of Doppler modality images for the current patient study.
- the cardiac features are then measured during a measurement process (block 310 of FIG. 3 ), which in one embodiment may comprises block 438 - 448 .
- the process of measuring cardiac features may begin by quantifying a plurality of measurements using the annotations.
- the 2D pipeline measures for the 2D images left/right ventricle, left/right atriums, left ventricular outflow (LVOT) and pericardium (block 438 ).
- the Doppler modality image pipeline measures blood flow velocities (block 440 ).
- volumetric measurements of chamber size are conducted on the systolic and diastolic frames of the video, and image processing techniques mimic a trained clinician at measuring the volume using the method of disks (MOD).
- MOD the method of disks
- a center line is extracted and smoothed, and then the peaks and valleys are measured in order to determine the minimum and maximum deviations over the cardiac cycle.
- a mask is created to isolate parts of the waveform.
- a sliding window is then run across the trace to identify one full heart cycle, in combination with heart rate data from the DICOM tags, to use as a template. This template is then used to identify all other heart cycles in the image. Peak detection is then performed on each cycle and then run through an algorithm to identify which part of the heart cycle each peak represents.
- CW image views from the annotations of the trace of the blood flow, curve fitting is performed on the annotation to then quantify the desired measurements.
- a mask is created to isolate parts of the waveform.
- a sliding window is then run across the trace to identify one full heart cycle, in combination with heart rate data from the DICOM tags, to use as a template. This template is then used to identify all other heart cycles in the image. Peak detection is then performed on each cycle and then run through an algorithm to identify which part of the heart cycle each peak represents.
- FIGS. 10 A and 10 B are diagrams graphically illustrating structural measurements automatically generated from annotations of cardiac chambers in a 2D image, and velocity measurements automatically generated from annotations of waveforms in a Doppler modality, respectively.
- the measurement table below list the measurements that may be compiled by the echo workflow engine 12 according to one embodiment.
- LAESV MOD A2C Left Atrial End Systolic Volume in A2C calculation based on Method Of Discs LAESVi MOD A2C Left Atrial End Systolic Volume in A2C calculation based on Method Of Discs indexed to BSA LAL A2C Left Atrial End Sysolic Length measured in A2C
- Ao index Ascending Aorta diameter index Sinus valsalva index Sinus valsalva diameter indexed to BSA IVC max Inferior Vena Cava maximum diameter IVC min Inferior Vena Cava minimum diameter IVC Collaps Inferior Vena Cava collaps RVIDd mid Right Ventricular Internal Diameter at mid level (measured end diastole) RVOT prox Right Ventricular Outflow Tract proximal diameter RVOT dist Right Ventricular Outflow Tract distal diameter RV FAC Right Ventricular Fractional Area Change TEI index RVAWT Right Ventricular Anterior Wall Thickness TrV-E Tricuspid valve E wave TrV-A Tricuspid valve A wave TrV E/A Tricuspid valve E/A ratio TrV DecT Tricuspid valve deceleration time MV Vmax Mitral valve maximum velocity MV Vmean Mitral valve mean velocity MV VTI Mitral valve velocity time intergal
- RV GLS Right Ventricular Global Longitudinal Strain (mean) RV GLS (A4C) Right Ventricular Global Longitudinal Strain measured in A4C RV GLS (A2C) Right Ventricular Global Longitudinal Strain measured in A2C RV GLS (A3C) Right Ventricular Global Longitudinal Strain measured in A3C LA GLS Left Atrial Global Longitudinal Strain (mean) LA GLS (A4C) Left Atrial Global Longitudinal Strain measured in A4C LA GLS (A2C) Left Atrial Global Longitudinal Strain measured in A2C LA GLS (A3C) Left Atrial Global Longitudinal Strain measured in A3C RA GLS Right Atrial Global Longitudinal Strain (mean) RA GLS (A4C) Right Atrial Global Longitudinal Strain measured in A4C RA GLS (A2C) Right Atrial Global Longitudinal Strain measured in A2C
- the echo workflow engine 12 maintains measurement confidence scores corresponding to the measured left/right ventricles, left/right atriums, LVOTs, pericardiums and measured velocities.
- the echo workflow engine 12 filters out echo images having measurement confidence scores that fail to meet a threshold, i.e., low measurement confidence scores (block 442 ).
- Measurement of cardiac features continues with calculating longitudinal strain graphs using the annotations generated by the CNNs (block 444 ). Thereafter, a fifth CNN is optionally used to detect pericardial effusion 446 .
- FIG. 11 is a diagram graphically illustrating measurements of global longitudinal strain that were automatically generated from the annotations of cardiac chambers in 2D images.
- the echo workflow engine 12 selects as best measurement data the measurements associated with cardiac chambers with the largest volumes, and saves with the best measurement data, image location, classification, annotation and other measurement data associated with the best measurements (block 447 ).
- FIG. 12 A is a diagram graphically illustrating an example set of best measurement data 1200 based on largest volume cardiac chambers and the saving of the best measurement data 1200 to a repository, such as database 16 of FIG. 1 .
- the echo workflow engine 12 then generates conclusions by inputting the cardiac biomarker measurements and the best measurement data 1200 to a set of rules based on international measurement guidelines to generate conclusions for medical decisions support (block 448 ).
- the following is an example rule set based on International cardiac guidelines in which the HF diagnosis is based on a point system:
- FIG. 12 B is a diagram graphically illustrating the input of normal LV EF measurements into a set of rules to determine a conclusion that the patient has normal diastolic function, diastolic dysfunction, or indeterminate.
- a report is generated and output ( FIG. 3 block 314 ), which may comprise blocks 450 - 456 .
- Report generation may begin by the echo workflow engine 12 outputting the cardiac biomarker measurements and the best measurement data 1200 to a JSON file for flexibility of export to other applications (block 450 ).
- FIG. 13 is a diagram graphically illustrating the output of classification, annotation and measurement data to an example JSON file.
- a lightweight browser-based user interface displayed showing a report that visualizes the cardiac biomarker measurements and the best measurement data 1200 from the JSON file and that is editable by a user (e.g., doctor/technician) for human verification (block 452 ).
- a lightweight web browser is a web browser that is optimized to reduce consumption of system resources, particularly to minimize memory footprint, and by sacrificing some of the features of a mainstream web browser.
- any edits made to the data are stored in the database 16 and displayed in the UI.
- the cardiac biomarker measurements and the best measurement data 1200 are automatically compared to current International guideline values and any out of range values are highlighted for the user (block 454 ).
- FIG. 14 is a diagram illustrating a portion of an example report showing highlighting values that are outside the range of International guidelines.
- the user is provided with an option of generating a printable report showing an automated summary of Main Findings (i.e., a conclusion reached after examination) and underlining measurements of the patient's health (block 456 ).
- FIG. 15 is a diagram illustrating a portion of an example report of Main Findings that may be printed and/or displayed by the user.
- the automated workflow of the echo workflow engine 12 may end at block 456 .
- the process may continue with advance functions, as described below.
- FIG. 4 B is a flow diagram illustrating advanced functions of the echo workflow engine.
- the echo workflow engine 12 takes as inputs values of the cardiac biomarkers and specific measurements that were automatically derived using machine learning (see block 310 ), and analyzes the input measurements to determine disease diagnosis/prediction/prognosis versus both disease and matched controls and normal patient controls (block 460 ).
- the echo workflow engine 12 may use the disease predictions to perform diagnosis of any combination of: cardiac amyloidosis, hypertrophic cardiomyopathy, restrictive pericarditis, cardiotoxity, early diastolic dysfunction and Doppler free diastolic dysfunction assessment (block 462 ).
- a prognosis in the form of an automated score may then be generated to predict mortality and hospitalizations in the future (block 464 ).
- Echocardiography is key for the diagnosis of heart failure with preserved ejection fraction (HFpEF).
- HFpEF preserved ejection fraction
- the echo workflow engine 12 further generates a diagnostic score for understanding predictions (block 466 ). Using machine learning, the echo workflow engine 12 validates the diagnostic score against invasively measured pulmonary capillary wedge pressure (PCWP), and determines the prognostic utility of the score in a large HFpEF cohort.
- PCWP pulmonary capillary wedge pressure
- the echo workflow engine 12 takes as the inputs values, including the measurements that were automatically derived using machine learning workflow, and analyzes the input values using an HFpEF algorithm to compute the HFpEF diagnostic score.
- echocardiogram features of 233 patients with HFpEF were compared to 273 hypertensive controls with normal ejection fraction but no heart failure.
- An agnostic model was developed using penalized logistic regression model and Classification and Regression Tree (CART) analysis.
- CART Classification and Regression Tree
- the association of the derived echocardiogram score with invasively measured PCWP was investigated in a separate cohort of 96 patients.
- the association of the score with the combined clinical outcomes of cardiovascular mortality of HF hospitalization was investigated in 653 patients with HFpEF from the Americas echocardiogram sub study of the TOPCAT trial.
- left ventricular ejection fraction (LVEF ⁇ 60%), peak TR velocity (>2.3 m/s), relative wall thickness (RWT>0.39 mm), interventricular septal thickness (>12.2 mm) and E wave (>1 m/s) are selected as the most parsimonious combination of variables to identify HFpEF from hypertensive controls.
- a weighted score (range 0-9) based on these 5 echocardiogram variables had a combined area under the curve of 0.9 for identifying HFpEF from hypertensive controls.
- FIGS. 16 A and 16 B are diagrams showing a graph A plotting PCWP and HFpEF scores, and a graph B plotting CV mortality or hospitalization for HF, respectively.
- the echocardiographic score can distinguish HFpEF from hypertensive controls and is associated with objective measurements of severity and outcomes in HFpEF.
- the echo workflow engine 12 incorporates a federated training platform for effectively training the assortment of the neural networks employed by the machine learning layer 200 ( FIG. 2 ), as shown in FIG. 17 .
- FIG. 17 is a diagram illustrating a federated training platform associated with the automated clinical workflow system.
- the federated training platform 1700 comprises the echo workflow engine 1701 executing on one or more servers 1702 in the cloud.
- the echo workflow engine 1701 comprises multiple neural networks (NNs) 1708 , which may include some combination of GANs and CNNs, for example.
- the servers 1702 and echo workflow engine 1701 are in network communication with remote computers 1703 a , 1703 b , 1703 n (collectively computers 1703 ) located on premises at respective laboratories 1704 (e.g., lab 1 , lab 2 . . . , lab N).
- Each of the laboratories 1704 maintains cardiac biomarker and echo (image) biomarker file archives referred to herein as cardiac and echo biomarker files 1706 a , 1706 b . . . , 1706 N (collectively echo image files 1706 ) of patient cohorts.
- the laboratories 1704 may comprise a hospital or clinical lab environment where Echocardiography is performed as a diagnostic aid in cardiology for the morphological and functional assessment of the heart.
- doctors typically select a small subset of the available videos from the echo image files, and may only measure about two of the frames in those videos, which typically may have 70-100 image frames each.
- cardiac biomarkers have yet to be analyzed by machine learning.
- each lab's cardiac and echo biomarker files 1706 may treat the image file archives as proprietary (graphically illustrated by the firewall), and thus do not allow their cardiac and echo biomarker files 1706 to leave the premises, which means the cardiac and echo biomarker files 1706 are unavailable as a source of training data.
- the federated training platform 1700 unlocks the proprietary cardiac and echo biomarker files 1706 of the separate laboratories 1704 . This is done by downloading and installing lightweight clients and a set of NNs 1708 a , 1708 b , 1708 c on computers 1703 a , 1703 b , 1703 c (collectively computers 1703 ) local to the respective labs 1704 .
- lightweight client executing on computer 1703 a of a first lab accesses the first lab's cardiac and echo biomarker files 1706 a and uses those cardiac and echo biomarker files 1706 a to train the NNs 1708 a and upload a first trained set of NNs back to the server 1702 after training.
- the first set of trained NNs 1708 are then trained at a second lab (e.g., lab 2 ) by downloading the lightweight clients and NNs 1708 b the computer 1703 b located at the second lab 2 .
- the lightweight client executing on the computer 1703 b of the second lab can then access the second lab's cardiac and echo biomarker files 1706 b and use those cardiac and echo biomarker files 1706 b to continue to continue to train the NNs 1708 b and to upload a second trained of NNs set back to the server 1702 .
- This process may continue until the NN's complete training at the last lab N by the lightweight client executing on the computer 14 N of the last lab N to access lab N's cardiac and echo biomarker files 1706 N to train the NNs and to upload a final trained set of neural networks to the server 1702 .
- the final train set of neural networks are then used in analysis mode to automatically recognize and analyze the cardiac and echo biomarkers in the patient studies of the respective labs 1704 .
- the federated training platform 1700 results in a highly trained set of NNs 1708 that produce measurements and predictions with a higher degree of accuracy. Another benefit is that federated training platform 1700 unlocks and extracts value from the existing stores of cardiac and echo biomarker data.
- the cardiac and echo biomarker files 1706 from the laboratories 1704 previously represented vast numbers of cardiac and echo biomarker data from past patient studies and clinical trials that sat unused and unavailable for machine learning purposes because the images are unstructured, views are un-labelled, and most of the images were ignored.
- these unused and unavailable echo images are now processed by the lightweight client of the echo workflow engine 1701 to create labelled echo images that are stored in structured image databases 1710 a , 1710 b . .
- the structured image databases remain located on premises at the individual labs 1704 to comply with the security requirements (of the labs 1704 and/or the echo workflow engine 1701 ).
- the federated training platform 1700 provides access to structured cardiac and echo biomarker databases 1710 in multiple lab locations to allow distributed neural network training and validation of disease prediction across multiple patient cohorts without either the original cardiac biomarker data in files 1706 or the labelled echo image files in the structured database 1710 ever having to leave the premise of the labs 1704 .
- the echo workflow engine is configured to enhance functioning of a mobile ultrasound device 24 ( FIG. 1 ).
- a mobile ultrasound device 24 FIG. 1
- Commercially available mobile or hand-held ultrasound devices 24 are typically not available with artificial intelligence capabilities or analysis, and simply capture echocardiogram images.
- the echo workflow engine may be implemented with or without cardiac biomarker measurements and/or federated training.
- FIG. 18 is a diagram illustrating an automated clinical workflow system embodiment where the echo workflow engine is configured to provide a mobile ultrasound device 24 with automatic recognition and measurements of 2D and Doppler modality Echocardiographic images.
- the echo workflow engine may run in the standalone configuration in which the echo workflow engine executes within a computer 1814 .
- the computer 1814 is implemented as a tablet computer, but the computer 1814 may comprise any computer form factor.
- the echo work engine may run in a connected configuration comprising the echo workflow engine 1812 A executing on one or more servers 1834 in communication over network (e.g., the Internet) 1826 with an echo workflow client 1812 B executing on computer 1814 .
- the standalone embodiment for the echo workflow engine and the connected configuration will be referred to collectively as echo workflow engine 8112 .
- the computer 1814 is in electronic communication (wirelessly or wired) with peripheral devices such as an ultrasound imaging device, or simply ultrasound device.
- the ultrasound device may comprise a mobile ultrasound device 1824 , but any form factor may be used.
- the mobile ultrasound device 1824 includes a display device, a user interface (UI), and a transducer or probe that captures echocardiogram images of a patient's organ (e.g., a heart). As the transducer captures echocardiogram images, the images are displayed in the UI on the display device in real time.
- the mobile ultrasound device 1824 may comprise a tablet computer, a laptop or a smartphone.
- the computer 14 may be located in a hospital or clinical lab environment where Echocardiography is performed as a diagnostic aid in cardiology for the morphological and functional assessment of the heart.
- the echo workflow engine 1812 enhances the mobile ultrasound device 1824 by providing simultaneous acquisition and AI recognition of the echocardiogram (echo) images.
- software is either added to the mobile ultrasound device 1824 or existing software of the mobile ultrasound device 1824 is modified to operate with the echo workflow engine 1812 . That is the mobile ultrasound device 1824 may be modified to transmit echo images to the echo workflow engine, and receive and display the view classifications and the report, as described in FIG. 19 .
- the echo workflow engine 1812 may be incorporated into, and executed within, the mobile ultrasound device 1824 itself.
- FIG. 19 is a flow diagram for enhancing an ultrasound device to perform AI recognition of echocardiogram images.
- the process may begin by the echo workflow engine receiving the echo images (which may include videos) that are captured by the mobile ultrasound device 1824 and displayed in a user interface (UI) of the ultrasound device (block 1900 ).
- the echo workflow engine receiving the echo images (which may include videos) that are captured by the mobile ultrasound device 1824 and displayed in a user interface (UI) of the ultrasound device (block 1900 ).
- UI user interface
- FIG. 20 A is a diagram illustrating acquisition of echo images by the mobile ultrasound device 1824 .
- a user e.g., a sonographer, a technician or even an untrained user
- Measurements of the structure and blood flows are typically made using 2D slices of the heart and the position of the mobile ultrasound device 24 is varied during an echo exam to capture different anatomical sections of the heart from different viewpoints.
- the technician has the option of adding to these 2D echo images a waveform captured from various possible modalities including: continuous wave Doppler, m-mode, pulsed wave Doppler and pulsed wave tissue Doppler.
- the echo images may be stored as a patient study in database 16 and image file archive 18 ( FIG. 1 ) by the computer 1814 , the mobile ultrasound device 1824 or both.
- the echo workflow client 1812 B may store the echo images or otherwise transmit the echo images over the network 1826 to the echo workflow engine 1812 on the servers 1843 for storage as the patient study.
- the echo workflow engine 1812 processes the echo images using one or more neural networks to automatically classify by view type, i.e., which angle of the heart is captured (block 1902 ).
- the echo workflow engine 1812 then provides even an untrained user real-time feedback by simultaneously displaying the view type of the echo images in the UI of the mobile ultrasound device 1824 along with display of the echo images (block 1904 ). See for example, view classification blocks 304 and 306 in FIG. 4 A .
- FIG. 20 B is a diagram of a user interface displayed by the mobile ultrasound device 1824 .
- the UI 2000 displays an echo video (e.g., a series of echo images) as normal, but according to one embodiment, the UI 2000 is further configured to display real-time feedback to the user alongside the echo images (shown), or overlaid on the echo images.
- the echo workflow engine 1812 uses AI to automatically perform echo image analysis to detect and display the current view type 2002 , which in the example shown is “PLAX”. After all the required views are captures, the UI may also display an option 2004 for the user to view a report of echo image measurements generated by the echo workflow engine 1812 .
- the process continues with the echo workflow engine 1812 generating a report showing calculated measurements of features in the echo images (block 1906 ).
- the echo workflow engine 1812 displays the report showing the calculated measurements on a display device (block 1908 ).
- the workflow client 1812 b may transmit the report showing the calculated measurements to the ultrasound device 824 for display in the UI.
- the calculated measurements may be generated by the neural networks segmenting regions of interest in the 2D images to produce segmented 2D images, segmenting the Doppler modality images to generate waveform traces to produce segmented Doppler modality images, and using both the segmented 2D images and the segmented Doppler modality images to calculate measurements of cardiac features for both left and right sides of the heart.
- FIGS. 20 C, 20 D and 20 E are diagrams illustrating example pages of the report showing calculated measurements of features in the echo images.
- the report may be displayed in the UI 2006 of the mobile ultrasound device 1824 .
- FIG. 20 C shows that the report may comprise multiple pages of various types of information.
- page 1 of the report may include an ID of the patient, processing and visitation dates, a Main findings section showing of features and conclusions (e.g., normal, abnormal and the like), and a running video of an echo image.
- the UI 206 may display the report in a scrollable window that allows the user to scroll down to view various pages of the report.
- FIG. 20 D show page 2 of the report, which may display feature measurements for the left ventricle.
- the report may display a UI control next to one or more of the features for the user to select to display additional details. For example, in response to the user clicking on a UI control next to “LVEF MOD biplane”, the report may display information shown in FIG. 20 E .
- FIG. 20 E shows that responsive to the user selecting “LVEF MOD biplane”, a window expands to display “ASE and EACI 2015 Guidelines—Recommendations for Cardiac Chamber Quantification” in addition to a corresponding echo image from the patient.
- the user may click on “Male” or “Female” to see different value ranges. If the user selects the feature “LVPWd”, the report may display a full screen video, rather than an expandable window.
- FIG. 21 is a flow diagram showing processing by the echo workflow engine in the connected configuration comprising the echo workflow client 1812 B in network communication with the echo workflow engine 1812 A executing on one or more servers 1834 .
- the process may begin by the echo workflow client 1812 B receiving a user command to connect to the mobile ultrasound device 1824 (block 2100 ).
- the echo workflow client 1812 B may display a list of available devices via Bluetooth for user selection.
- the echo workflow client 1812 B receives a command from the user to record echo images and transmits a record command to the mobile ultrasound device 1824 (block 2102 ).
- the mobile ultrasound device 1824 Responsive to receiving the record command, the mobile ultrasound device 1824 initiates echo image recording and transmits captured echo images to the echo workflow client 1812 B for screen sharing (block 2104 ).
- the echo workflow client 1812 B receives the echo images from the mobile ultrasound device 1824 and transmits the echo images to the echo workflow engine 1812 A (block 2106 ).
- the echo images may be stored and associated with a patient study by either the echo workflow client 1812 B or the echo workflow engine 1812 A.
- the echo workflow engine 1812 A may be distributed across a prediction server and a job server (not shown).
- the echo workflow client 1812 B may be configured to send single echo images to the prediction server and send videos to the job server for view classification.
- the echo workflow client 1812 B determines if there are more view types to be captured (block 2014 ).
- the echo workflow client 1812 B may utilize a predetermined workflow or a list of view types to capture. Responsive to determining there are more view types to be captured, the echo workflow client 1812 B may transmit a prompt to the mobile ultrasound device 1824 for the user to capture the next view type (block 2116 ). The mobile ultrasound device 1824 receives and displays the prompt in the UI alongside the captured echo images (block 2118 ).
- the echo workflow client 1812 B displays the report on the display device of the computer 1814 .
- the echo workflow client 1812 B may display a UI component, such as a “report” button or other control for user selection that causes display of the report.
- the echo workflow client 1812 B may, instead of or in addition to, transmit the report to the mobile ultrasound device for display in the UI of the mobile ultrasound device 1824 .
- the advantages of the present embodiment provide a mobile tool with automated, AI based decision support and analysis of both 2D and Doppler echocardiogram images, thereby providing caregivers with a versatile, point-of care solution for triage, diagnosis, prognosis and management of cardiac care.
- the UI 2000 of the mobile ultrasound device conventionally displays echo images, but is further configured to display along with the echo images real-time feedback to the user.
- the real-time feedback further includes AI-based guidance for the ultrasound device to improve capture of echo image view types.
- the AI-based guidance may include continuously attempting AI recognition of the echo images as they are being captured combined with displaying in the UI of the mobile ultrasound device 1824 feedback indications to the user of which directions to move the probe 24 ′ so the probe 24 ′ can be placed in a correct position to capture and successfully recognize the echo image.
- software is either added to the mobile ultrasound device 1824 or existing software of the mobile ultrasound device 1824 is modified to operate with the echo workflow engine 1812 . That is the mobile ultrasound device 1824 may be modified to transmit echo images to the echo workflow engine, and receive and display the view type classifications. In yet another embodiment the echo workflow engine 1812 may be incorporated into, and executed within, the mobile ultrasound device 1824 itself.
- FIG. 22 A illustrates a flow diagram of an AI-based guidance process for an ultrasound device to improve capture of echo image views.
- the process may begin by the echo workflow engine 1812 executing on a processor and receiving the echo images that are displayed in the UI of the mobile ultrasound device 1824 (block 2202 ).
- the echo workflow engine 1812 processes the echo images using one or more neural networks to continuously attempt to automatically classify the echo images by view type and generates corresponding classification confidence scores (block 2204 ).
- the echo workflow engine 1812 simultaneously displays the view type of the echo images in the UI of the ultrasound device along with the echo images (block 2206 ). In one embodiment, the confidence scores may also be displayed.
- the echo workflow engine 1812 displays in the UI of the mobile ultrasound device feedback indications to the user, including which directions to move a probe of the mobile ultrasound device so the probe can be placed in a correct position to capture and successfully classify the echo image (block 2208 ).
- FIG. 22 B is a diagram of a user interface displayed by the mobile ultrasound device 1824 and is similar to the diagram shown in FIG. 20 B where the UI 2130 displays a series of echo images (e.g., a video) 2132 in the UI 2130 and simultaneously displays real-time feedback indications 2134 in the UI 2130 alongside the echo images, or overlaid on the echo images 2132 .
- the echo workflow engine 1812 uses AI to not only automatically perform echo image analysis to detect and display the current view type, e.g. “PLAX”, but also to detect and display feedback indications 2134 of which directions to move the probe 24 ′ of the mobile ultrasound device 1824 .
- the current view type e.g. “PLAX”
- the feedback indications 2134 can be displayed as any combination of alphanumeric characters and graphical objects, audio, and any combination thereof.
- the feedback indications 2134 may comprise text, symbols, icons, emoji's, pre-recorded digital voice instructions, or any combination thereof.
- the feedback indications may further be displayed as both informational guidance 2134 A, directional guidance instructions 2134 B, and a combination thereof as shown.
- Informational guidance 2134 A relates to display of information and may include setup instructions, a list of view types to be captured, the view type currently being captured, confidence scores of the view types, remaining view types to be captured, all view types captured, and any combination thereof.
- FIG. 22 B shows an example where the informational guidance 2134 A comprises the current view being acquired is “PLAX, a percent completion of the acquisition, and a list of view types to be acquired.
- Directional guidance instructions 2134 B relate to instructions that guide the user in moving the probe and may include i) macro-guidance instructions that instruct the user to adjust alignment or position of the probe to a known view type, and ii) micro-guidance instructions that instruct the user to optimize a view type of an echo image in progress, or a combination of both.
- Both the macro guidance instructions and the micro-guidance instructions may include probe movement instructions 2134 B such as: up/down or side-side, diagonal movements (up left/up right, down left/down right) rotation clockwise or counter-clockwise, tilt up/down or side-side, hold, or a combination thereof.
- FIG. 22 B shows an example where the directional guidance instructions 2134 B comprises an instruction to “Hold Still, Acquiring Image”.
- One or more of the directional guidance instructions 2134 B may be associated with a distance value, e.g., “Move the probe to the left 1 inch”, or a time value, e.g., “Hold the probe still for 6 seconds”.
- FIGS. 22 C- 22 E are diagrams showing a progression of feedback indications 2134 continuing from FIG. 22 B .
- FIG. 22 C shows the informational guidance 2134 A has been updated to include indications that the current view type being captured is “A4C”, the percent completion of the acquisition, and the list of view types to be acquired, where a checkmark is displayed next to the captured view type PLAX to indicate that view type has been successfully captured and recognized.
- the directional guidance instructions 2134 B have been updated to display to “Please Adjust Probe” along with a probe movement instruction comprising a graphical clockwise arrow.
- FIG. 22 D shows the informational guidance 2134 A has been updated to include indications that the current view type being captured is “A2C”, the percent completion of the acquisition, and the list of view types to be acquired, where a checkmark is displayed next to the captured view type PLAX and A4C to indicate that these view types have been successfully captured and recognized.
- the directional guidance instructions 2134 B have been updated to display “Please Adjust Probe” along with a probe movement instruction comprising a graphical twisting left arrow.
- FIG. 22 E shows the informational guidance 2134 A has been updated to include indications that the all “All View Types Acquired!”, a blank percent completion of the acquisition, and the list of view types acquired with checkmarks.
- the directional guidance instructions 2134 B are no longer needed and not displayed since the view type captures have completed.
- This process may begin by the echo workflow engine 1812 determining if the classification confidence scores meet a predetermined threshold (block 2208 A).
- the predetermined threshold may be greater than 60-75% and may be configurable. Responsive to the confidence scores meeting the predetermined threshold, the echo workflow engine 1812 displays the view type and a directional guidance instruction to the user to optimize the view type until successful capture (block 2208 B).
- the echo workflow engine 1812 displays an estimated view type and a feedback instruction in a form of directional guidance instructions to adjust alignment or position of the probe to a known view type (block 2108 C), and this process continues until the classification score meets the threshold.
- the echo workflow engine 1812 determines if there is another view type to capture, e.g., such as defined in a workflow (block 2208 D). If so, the process continues with processing of the echo images (block 2204 ). Otherwise, the echo workflow engine 1812 may optionally display informational feedback that all views have been captured and the process ends (block 2208 E).
- the process may further include prior to echo image capture, optionally displaying feedback instructions in a form of setup instructions in the UI of the mobile ultrasound device 1824 . This may be of aid to a novice user in terms of receiving help how to properly setup the mobile ultrasound device 1824 and initially place the probe 24 ′.
- the present embodiment provides an ultrasound device user with immediate feedback on whether images acquired in a mobile setting are captured in the correct angle and are of sufficient quality to provide suitable measurements and diagnosis of the patient's cardiac condition.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Primary Health Care (AREA)
- Theoretical Computer Science (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Data Mining & Analysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Evolutionary Computation (AREA)
- Mathematical Physics (AREA)
- Software Systems (AREA)
- Computing Systems (AREA)
- General Physics & Mathematics (AREA)
- Computational Linguistics (AREA)
- Artificial Intelligence (AREA)
- General Engineering & Computer Science (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Databases & Information Systems (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
Description
Measurement Name | Measurement Description |
LAESV MOD A2C | Left Atrial End Systolic Volume in A2C calculation |
based on Method Of Discs | |
LAESVi MOD A2C | Left Atrial End Systolic Volume in A2C calculation |
based on Method Of Discs indexed to BSA | |
LAL A2C | Left Atrial End Sysolic Length measured in A2C |
LVEDV MOD A2C | Left Ventricular End Diastolic Volume in A2C |
calculation based on Method Of Discs | |
LVEDVi MOD A2C | Left Ventricular End Diastolic Volume in A2C |
calculation based on Method Of Discs indexed to BSA | |
LVEF MOD A2C | Left Ventricular Ejection Fraction in A2C based on |
Method Of Discs | |
LVESV MOD A2C | Left Ventricular End Systolic Volume in A2C |
calculation based on Method Of Discs | |
LVESVi MOD A2C | Left Ventricular End Systolic Volume in A2C |
calculation based on Method Of Discs indexed to BSA | |
LV length A2C | Left Ventricular Length measured in A2C |
LAESV MOD A4C | Left Atrial End Systolic Volume in A4C calculation |
based on Method Of Discs | |
LAESVi MOD A4C | Left Atrial End Systolic Volume in A4C calculation based |
on Method Of Discs indexed to BSA | |
LAL A4C | Left Atrial End Systolic Length measured in A4C |
LAW A4C | Left Atrial End Systolic Width measurement in A4C |
LA area A4C | Left Atrial Area measured in A4C |
LAESV A-L A4C | Left Atrial End Systolic Volume in A4C calculation |
based on Area-Length method | |
LVEDV MOD A4C | Left Ventricular End Diastolic Volume in A4C |
calculation based on Method Of Discs | |
LVEDVi MOD A4C | Left Ventricular End Diastolic Volume in A4C |
calculation based on Method Of Discs indexed to BSA | |
LVEF MOD A4C | Left Ventricular Ejection Fraction in A4C based on |
Method Of Discs | |
LVESV MOD A4C | Left Ventricular End Systolic Volume in A4C |
calculation based on Method Of Discs | |
LVESVi MOD A4C | Left Ventricular End Systolic Volume in A4C |
calculation based on Method Of Discs indexed to BSA | |
LV length A4C | Left Ventricular Length measured in A4C |
LVAd A4C | Left Ventricular Area measured at end diastole in A4C |
TAPSE | Tricuspid Annular Plane Systolic Excursion |
DecT | Deceleration Time of early diastolic MV transmitral flow |
E/A ratio | Ratio of early and late diastolic transmitral flow |
MV-A | Late diastolic transmitral flow |
MV-Adur | Duration of late diastolic transmitral flow |
MV-E | Early diastolic transmitral flow |
e′ lateral | Early diastolic tissue velocity taken from the lateral |
region | |
e′ mean | Mean early diastolic tissue velocity (mean of lateral |
and septal region) | |
e′ septal | Early diastolic tissue velocity taken from the septal |
region | |
E/e′ lateral | Ratio of early transmitral flow and early diastolic tissue |
velocity taken form the lateral region | |
E/e′ septal | Ratio of early transmitral flow and early diastolic tissue |
velocity taken form the septal region | |
E/e′ mean | Ratio of early transmitral flow and mean diastolic |
tissue velocity | |
a′ lateral | Late diastolic tissue velocity taken from the lateral |
region | |
a′ septal | Late diastolic tissue velocity taken from the septal |
region | |
s′ lateral | Systolic tissue velocity taken from the lateral region |
s′ septal | Systolic tissue velocity taken from the septal region |
LAESV A-L biplane | Left Atrial End Systolic Volume biplane calculation |
based on Area-Length method | |
LAESV MOD biplane | Left Atrial End Systolic Volume biplane calculation |
based on Method Of Discs | |
LAESVi MOD biplane | Left Atrial End Systolic Volume biplane calculation |
based on Method Of Discs indexed to BSA | |
LAESVi A-L biplane | Left Atrial End Systolic Volume biplane calculation |
based on Area-Length method indexed to BSA | |
LVCO MOD biplane | Left Ventricular Cardiac Output biplane calculation |
based on Method Of Discs | |
LVEDV MOD biplane | Left Ventricular End Diastolic Volume biplane |
calculation based on Method Of Discs | |
LVEDVi MOD biplane | Left Ventricular End Diastolic Volume biplane |
calculation based on Method Of Discs indexed to BSA | |
LVEF MOD biplane | Left Ventricular Ejection Fraction biplane based on |
Method Of Discs | |
LVESV MOD biplane | Left Ventricular End Systolic Volume biplane |
calculation based on Method Of Discs | |
LVESVi MOD biplane | Left Ventricular End Systolic Volume biplane |
calculation based on Method Of Discs indexed to BSA | |
LVSV MOD biplane | Left Ventricular Stroke Volume biplane calculation |
based on Method of Disks | |
AoV Vmax | Aortic Valve maximum Velocity |
AoV Vmean | Aortic Valve mean Velocity |
AoV Pmax | Aortic Valve maximum Pressure gradient |
LVOT Vmax | Left Ventricular Outflow Tract maximum Velocity |
LVOT Vmean | Left Ventricular Outflow Tract mean Velocity |
IVSd | Inter Ventricular Septal thickness measured end |
diastolic | |
LV mass | Left Ventricular mass |
LVIDd | Left Ventricular internal Diameter measured at end |
diastole | |
LVIDd index | Left Ventricular internal Diameter measured at end |
diastole indexed to BSA | |
LVIDs | Left Ventricular internal Diameter measured at end |
systole | |
LVIDs index | Left Ventricular internal Diameter measured at end |
systole indexed to BSA | |
LVMi | Left Ventricular Mass indexed to BSA |
LVOT | Left Ventricular Outflow Tract diameter |
LVPWd | Left Ventricular Posterior Wall thickness measured |
end diastolic | |
RWT | Relative Wall Thickness |
LA area A2C | Left Atrial Area measured in A2C |
LAESV A-L A2C | Left Atrial End Systolic Volume in A2C calculation |
based on Area-Length method | |
LVAd A2C | Left Ventricular Area measured at end diastole in A2C |
LVAs A2C | Left Ventricular Area measured at end systole in A2C |
LVAs A4C | Left Ventricular Area measured at end systole in A4C |
PASP | Pulmonary Artery Systolic Pressure |
RAL | Right Atrial End Systolic Length |
RAW | Right Atrial End Systolic Width |
RAESV MOD A4C | Right Atrial end systolic Volume in A4C calculation |
based on Method Of Discs | |
RAESV A-L A4C | Right Atrial end systolic Volume in A4C calculation |
based on Area-Length method | |
RAESVi MOD A4C | Right Atrial end systolic Volume in A4C calculation |
based on Method Of Discs indexed to BSA | |
RA area | Right Atrial area |
RVIDd | Right Ventricular End Diastolic Internal Diameter |
RV area (d) | Right Ventricular Area (measured at end-diastole) |
RV area (s) | Right Ventricular Area (measured at end systole) |
LVOT Pmax | Left Ventricular Outflow Tract max pressure gradient |
LVOT Pmean | Left Ventricular Outflow Tract mean pressure gradient |
LVSV (Doppler) | Left Ventricular Stroke Volume based on Doppler |
LVOT VTI | Left Ventricular Outflow Tract Velocity Time Integral |
LVCO (Doppler) | Left Ventricular Cardiac Output (based on Doppler) |
LVCOi (Doppler) | Left Ventricular Cardiac Output (based on Doppler) |
indexed to Body Surface Area | |
LVSVi (Doppler) | Left Ventricular Stroke Volume (based on Doppler) |
indexed to Body Surface Area | |
TR Vmax | Tricuspid Regurgitation maximum velocity |
CSA LVOT | Crossectional Area of the LVOT |
Sinotub J | Sinotubular junction diameter |
Sinus valsalva | Sinus valsalva diameter |
Asc. Ao | Ascending Aorta diameter |
Asc. Ao index | Ascending Aorta diameter index |
Sinus valsalva index | Sinus valsalva diameter indexed to BSA |
IVC max | Inferior Vena Cava maximum diameter |
IVC min | Inferior Vena Cava minimum diameter |
IVC Collaps | Inferior Vena Cava collaps |
RVIDd mid | Right Ventricular Internal Diameter at mid level |
(measured end diastole) | |
RVOT prox | Right Ventricular Outflow Tract proximal diameter |
RVOT dist | Right Ventricular Outflow Tract distal diameter |
RV FAC | Right Ventricular Fractional Area Change |
TEI index | |
RVAWT | Right Ventricular Anterior Wall Thickness |
TrV-E | Tricuspid valve E wave |
TrV-A | Tricuspid valve A wave |
TrV E/A | Tricuspid valve E/A ratio |
TrV DecT | Tricuspid valve deceleration time |
MV Vmax | Mitral valve maximum velocity |
MV Vmean | Mitral valve mean velocity |
MV VTI | Mitral valve velocity time intergal |
MV PHT | Mitral valve pressure half time |
MVA (by PHT) | Mitral valve area (by pressure half time) |
RV e′ | Early diastolic tissue velocity taken from the right |
ventricular free wall region | |
RV a′ | Late diastolic tissue velocity taken from the right |
ventricular free wall region | |
RV s′ | Systolic tissue velocity taken from the right ventricular |
free wall region | |
RVCO | Right Ventricular Cardiac Output |
ULS | Unidimensional Longitudinal Strain |
Ao-arch | Aortic arch diameter |
Descending Ao | Descending Aortic diameter |
Ao-arch index | Aortic arch diameter indexed to BSA |
Descending Ao index | Descending Aortic diameter indexed to BSA |
LA GLS (reservoir) (A4C) | Left Atrial strain during systole measured in A4C |
LA GLS (conduit) (A4C) | Left Atrial strain during early diastole measured in A4C |
LA GLS (booster) (A4C) | Left Atrial strain during pre atrial contraction measured |
in A4C | |
LA GLS (reservoir) (A2C) | Left Atrial strain during systole measured in A2C |
LA GLS (conduit) (A2C) | Left Atrial strain during early diastole measured in A2C |
LA GLS (booster) (A2C) | Left Atrial strain during pre atrial contraction measured |
in A2C | |
LA GLS (reservoir) | Left Atrial strain during systole |
LA GLS (conduit) | Left Atrial strain during early diastole |
LA GLS (booster) | Left Atrial strain during pre atrial contraction |
LVSr-e (A4C) | Left Ventricular strain rate during early diastole |
measured in A4C | |
LVSr-a (A4C) | Left Ventricular strain rate during late diastole |
measured in A4C | |
LVSr-s (A4C) | Left Ventricular strain rate during systole measured in |
A4C | |
LVSr-e (A2C) | Left Ventricular strain rate during early diastole |
measured in A2C | |
LVSr-a (A2C) | Left Ventricular strain rate during late diastole |
measured in A2C | |
LVSr-s (A2C) | Left Ventricular strain rate during systole measured in |
A2C | |
LVSr-e | Left Ventricular strain rate during early diastole |
LVSr-a | Left Ventricular strain rate during late diastole |
LVSr-s | Left Ventricular strain rate during systole |
LASr-e (A4C) | Left Atrial strain rate during early diastole |
LASr-a (A4C) | Left Atrial strain rate during late diastole |
LASr-s (A4C) | Left Atrial strain rate during systole |
LASr-e (A2C) | Left Atrial strain rate during early diastole |
LASr-a (A2C) | Left Atrial strain rate during late diastole |
LASr-s (A2C) | Left Atrial strain rate during systole |
LASr-e | Left Atrial strain rate during early diastole |
LASr-a | Left Atrial strain rate during late diastole |
LASr-s | Left Atrial strain rate during systole |
AV-S (A4C) | Atrio Ventricular strain measured in A4C |
AV-S (A2C) | Atrio Ventricular strain measured in A2C |
AV-S | Atrio Ventricular strain |
Sr-Sav (A4C) | Atrio Ventricular strain rate during systole measured in |
A4C | |
Sr-Eav (A4C) | Atrio Ventricular strain rate during early diastole |
measured in A4C | |
Sr-Aav (A4C) | Atrio Ventricular strain rate during late diastole |
measured in A4C | |
Sr-Sav (A2C) | Atrio Ventricular strain rate during systole measured in |
A2C | |
Sr-Eav(A2C) | Atrio Ventricular strain rate during early diastole |
measured in A2C | |
Sr-Aav (A2C) | Atrio Ventricular strain rate during late diastole |
measured in A2C | |
Sr-Sav | Atrio Ventricular strain rate during systole |
Sr-Eav | Atrio Ventricular strain rate during early diastole |
Sr-Aav | Atrio Ventricular strain rate during late diastole |
LVVr-e (A4C) | Left Ventricular volume rate during early diastole |
measured in A4C | |
LVVr-a (A4C) | Left Ventricular volume rate during late diastole |
measured in A4C | |
LVVr-s (A4C) | Left Ventricular volume rate during systole measured |
in A4C | |
LVVr-e (A2C) | Left Ventricular volume rate during early diastole |
measured in A2C | |
LVVr-a (A2C) | Left Ventricular volume rate during late diastole |
measured in A2C | |
LVVr-s (A2C) | Left Ventricular volume rate during systole measured |
in A2C | |
LVVr-e | Left Ventricular volume rate during early diastole |
LVVr-a | Left Ventricular volume rate during late diastole |
LVVr-s | Left Ventricular volume rate during systole |
LAVr-e (A4C) | Left Atrial volume rate during early diastole measured |
in A4C | |
LAVr-a (A4C) | Left Atrial volume rate during late diastole measured in |
A4C | |
LAVr-s (A4C) | Left Atrial volume rate during systole measured in A4C |
LAVr-e (A2C) | Left Atrial volume rate during early diastole measured |
in A2C | |
LAVr-a (A2C) | Left Atrial volume rate during late diastole measured in |
A2C | |
LAVr-s (A2C) | Left Atrial volume rate during systole measured in A2C |
LAVr-e | Left Atrial volume rate during early diastole |
LAVr-a | Left Atrial volume rate during late diastole |
LAVr-s | Left Atrial volume rate during systole |
TLVd | Total Left heart volume end-diastolic |
TLVs | Total Left heart volume end-systolic |
TLVd (A4C) | Total Left heart volume end-diastolic measured in A4C |
TLVs (A4C) | Total Left heart volume end-systolic measured in A4C |
TLVd (A2C) | Total Left heart volume end-diastolic measured in A2C |
TLVs (A2C) | Total Left heart volume end-systolic measured in A2C |
Ar | Pulmonary vein Atrial reversal flow |
Ardur | Pulmonary vein Atrial reversal flow duration |
D | Pulmonary vein diastolic flow velocity |
S | Pulmonary vein systolic flow velocity |
S/D ratio | Ratio of Pulmonary vein systolic- and diastolic flow |
Vel. | |
RV GLS | Right Ventricular Global Longitudinal Strain (mean) |
RV GLS (A4C) | Right Ventricular Global Longitudinal Strain measured |
in A4C | |
RV GLS (A2C) | Right Ventricular Global Longitudinal Strain measured |
in A2C | |
RV GLS (A3C) | Right Ventricular Global Longitudinal Strain measured |
in A3C | |
LA GLS | Left Atrial Global Longitudinal Strain (mean) |
LA GLS (A4C) | Left Atrial Global Longitudinal Strain measured in A4C |
LA GLS (A2C) | Left Atrial Global Longitudinal Strain measured in A2C |
LA GLS (A3C) | Left Atrial Global Longitudinal Strain measured in A3C |
RA GLS | Right Atrial Global Longitudinal Strain (mean) |
RA GLS (A4C) | Right Atrial Global Longitudinal Strain measured in |
A4C | |
RA GLS (A2C) | Right Atrial Global Longitudinal Strain measured in |
A2C | |
RA GLS (A3C) | Right Atrial Global Longitudinal Strain measured in |
A3C | |
PV Vmax | Pulmonary Valve maximum Velocity |
PV Vmean | Pulmonary Valve mean Velocity |
PV Pmax | Pulmonary Valve maximum Pressure gradient |
PV Pmean | Pulmonary Valve mean Pressure gradient |
PV VTI | Pulmonary Valve Velocity Time Integral |
MV-Adur - Ardur | Difference between late diastolic transmitral flow and |
pulmonary vein atrial reversal flow duration | |
APC | Arteria pulmonalis communis |
LV eccentricity index | LV eccentricity index |
Mean % WT A2C | Mean percentual Wall Thickening of 6 segments in A2C |
AA-% WT | Percentile wall thickening of apical anterior segment |
AA-WTd | Wall thickness of apical anterior segment in diastole |
AA-WTs | Wall thickness of apical anterior segment in systole |
AI-% WT | Percentile wall thickening of apical inferior segment |
AI-WTd | Wall thickness of apical inferior segment in diastole |
AI-WTs | Wall thickness of apical inferior segment in systole |
BA-% WT | Percentile wall thickening of basal anterior segment |
BA-WTd | Wall thickness of basal anterior segment in diastole |
BA-WTs | Wall thickness of basal anterior segment in systole |
BI-% WT | Percentile wall thickening of basal interior segment |
BI-WTd | Wall thickness of basal interior segment in diastole |
BI-WTs | Wall thickness of basal interior segment in systole |
MA-% WT | Percentile wall thickening of mid anterior segment |
MA-WTd | Wall thickness of mid anterior segment in diastole |
MA-WTs | Wall thickness of mid anterior segment in systole |
MI-% WT | Percentile wall thickening of mid inferior segment |
MI-WTd | Wall thickness of mid inferior segment in diastole |
MI-WTs | Wall thickness of mid inferior segment in systole |
Pericardial effusion | Pericardial effusion |
Mean % WT A3C | Mean percentual Wall Thickening of 6 segments in A3C |
AAS-%WT | Percentile wall thickening of apical antero-septal |
segment | |
AAS-WTd | Wall thickness of apical antero-septal segment in |
diastole | |
AAS-WTs | Wall thickness of apical antero-septal segment in |
systole | |
AP-% WT | Percentile wall thickening of apical posterior segment |
AP-WTd | Wall thickness of apical posterior segment in diastole |
AP-WTs | Wall thickness of apical posterior segment in systole |
BAS-% WT | Percentile wall thickening of basal antero-septal |
segment | |
BAS-WTd | Wall thickness of basal antero-septal segment in |
diastole | |
BAS-WTs | Wall thickness of basal antero-septal segment in |
systole | |
BP-% WT | Percentile wall thickening of basal posterior segment |
BP-WTd | Wall thickness of basal posterior segment in diastole |
BP-WTs | Wall thickness of basal posterior segment in systole |
MAS-% WT | Percentile wall thickening of mid antero-septal |
segment | |
MAS-WTd | Wall thickness of mid antero-septal segment in |
diastole | |
MAS-WTs | Wall thickness of mid antero-septal segment in systole |
MP-% WT | Percentile wall thickening of mid posterior segment |
MP-WTd | Wall thickness of mid posterior segment in diastole |
MP-WTs | Wall thickness of mid posterior segment in systole |
Mean % WT A4C | Mean percentual Wall Thickening of 6 segments in A4C |
AL-% WT | Percentile wall thickening of apical lateral segment |
AL-WTd | Wall thickness of apical lateral segment in diastole |
AL-WTs | Wall thickness of apical lateral segment in systole |
AS-% WT | Percentile wall thickening of apical septal segment |
AS-WTd | Wall thickness of apical septal segment in diastole |
AS-WTs | Wall thickness of apical septal segment in systole |
BL-% WT | Percentile wall thickening of basal lateral segment |
BL-WTd | Wall thickness of basal lateral segment in diastole |
BL-WTs | Wall thickness of basal lateral segment in systole |
BS-% WT | Percentile wall thickening of basal septal segment |
BS-WTd | Wall thickness of basal septal segment in diastole |
BS-WTs | Wall thickness of basal septal segment in systole |
ML-% WT | Percentile wall thickening of mid lateral segment |
ML-WTd | Wall thickness of mid lateral segment in diastole |
ML-WTs | Wall thickness of mid lateral segment in systole |
MS-% WT | Percentile wall thickening of mid septal segment |
MS-WTd | Wall thickness of mid septal segment in diastole |
MS-WTs | Wall thickness of mid septal segment in systole |
Global % WT | Global percentual Wall Thickening of the Left Ventricle |
AoV Vmean | Aortic Valve mean Velocity |
AoV Pmean | Aortic Valve mean Pressure gradient |
AOV VTI | Aortic Valve Velocity Time Integral |
AVA Vmax | Aortic Valve Area (measured by max Vel.) |
AVA VTI | Aortic valve Area (measured by Velocity Time Integral) |
AVAi Vmax | Aortic Valve Area (measured by maximum Velocity) |
indexed to Body Surface Area | |
AVAi VTI | Aortic valve Area (measured by Velocity Time Integral) |
indexed to Body Surface Area | |
ivrt | IsoVolumic Relaxation Time |
LV GLS (A4C) | Left Ventricular Global Longitudinal Strain measured |
in A4C | |
LV GLS (A2C) | Left Ventricular Global Longitudinal Strain measured |
in A2C | |
LV GLS (A3C) | Left Ventricular Global Longitudinal Strain measured |
in A3C | |
LV GLS | Left Ventricular Global Longitudinal Strain (mean) |
-
- septal e′<7 cm/s, or
- lateral e′<10 cm/s, or
- Average E/e′>=15, or
- TR velocity>2.8 m/s and PASP>35 mmHg,
- then add 2 points.
-
- LAVI>34 ml/m2, or
- LVMI>=149/122 g/m2 (m/w) and RWT>0.42,
- then add 2 points.
-
- NT-proBNP>220 pg/ml, or
- BNP>80 pg/ml,
- then add 2 points.
-
- NT-proBNP>660 pg/ml, or
- BNP>240 pg/ml,
- then add 2 points.
-
- Average E/e′=9-14 or
- GLS<16%,
- then add 1 point.
-
- LAVI 29/34 ml/m2, or
- LVMI>115/95 g/m2 (m/w), or
- RWT>0.42, or
- LV wall thickness>=12 mm
- then add 1 point.
-
- NT-proBNP 125-220 pg/ml, or
- BNP 35-80 pg/ml,
- then add 1 point.
-
- NT-proBNP 365-660 pg/ml, or
- BNP 105/240 pg/ml,
- then add 1 point.
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/219,670 US12001939B2 (en) | 2018-12-11 | 2021-03-31 | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/216,929 US10631828B1 (en) | 2018-12-11 | 2018-12-11 | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and the diagnosis, prediction and prognosis of heart disease |
US16/833,001 US11301996B2 (en) | 2018-12-11 | 2020-03-27 | Training neural networks of an automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images |
US17/219,670 US12001939B2 (en) | 2018-12-11 | 2021-03-31 | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/833,001 Continuation-In-Part US11301996B2 (en) | 2018-12-11 | 2020-03-27 | Training neural networks of an automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images |
Publications (2)
Publication Number | Publication Date |
---|---|
US20210264238A1 US20210264238A1 (en) | 2021-08-26 |
US12001939B2 true US12001939B2 (en) | 2024-06-04 |
Family
ID=77366758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/219,670 Active 2040-03-28 US12001939B2 (en) | 2018-12-11 | 2021-03-31 | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
Country Status (1)
Country | Link |
---|---|
US (1) | US12001939B2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11301996B2 (en) * | 2018-12-11 | 2022-04-12 | Eko.Ai Pte. Ltd. | Training neural networks of an automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images |
US11446009B2 (en) * | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
US12001939B2 (en) * | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
US11931207B2 (en) * | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
EP4139880A4 (en) * | 2020-04-24 | 2024-04-10 | Spectrum Optix, Inc | Neural network supported camera image or video processing pipelines |
WO2024173602A2 (en) * | 2023-02-14 | 2024-08-22 | The Regents Of The University Of California | Systems and methods for automated diagnosis of disease related risk factors in 3d biomedical imaging |
WO2025039035A1 (en) * | 2023-08-21 | 2025-02-27 | Victor Chang Cardiac Research Institute | Method and system for assessing severity of stenosis |
Citations (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6514207B2 (en) | 2000-04-13 | 2003-02-04 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for processing echocardiogram video images |
US20040077027A1 (en) | 2002-07-11 | 2004-04-22 | Leong Ng | Assays and kits for detecting and monitoring heart disease |
US20040096919A1 (en) | 2002-11-18 | 2004-05-20 | Michelle Davey | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
US20040133083A1 (en) | 2002-11-13 | 2004-07-08 | Siemens Corporate Research Inc. | System and method for real-time feature sensitivity analysis based on contextual information |
US20050074088A1 (en) * | 2003-08-27 | 2005-04-07 | Matsushita Electric Industrial Co., Ltd. | X-ray inspection apparatus and X-ray inspection method |
US20050239138A1 (en) | 2004-03-15 | 2005-10-27 | Georg Hess | Use of cardiac hormones to assess risk of cardiovascular complication from volume overload |
US20050287613A1 (en) | 2002-11-18 | 2005-12-29 | George Jackowski | Polyclonal-polyclonal ELISA assay for detecting N-terminus-proBNP |
US20060166303A1 (en) | 2005-01-24 | 2006-07-27 | Eberhard Spanuth | Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs |
US7135329B2 (en) | 2002-11-18 | 2006-11-14 | Princeton Biomeditech Corporation | Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients |
US20060264764A1 (en) | 2005-05-18 | 2006-11-23 | Alejandro Ortiz-Burgos | System and method for non-invasively determining a left ventricular end-diastolic pressure |
US20060286681A1 (en) | 2003-11-07 | 2006-12-21 | Hans-Peter Lehmann | Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease |
US20070015208A1 (en) | 2004-07-07 | 2007-01-18 | Roche Diagnostics Operations, Inc. | Multimarker panel for diabetes type 1 and 2 |
US20070141634A1 (en) | 2003-06-30 | 2007-06-21 | Orion Diagnostica Oy Body Corporate | Assay |
US7264938B2 (en) | 2003-05-12 | 2007-09-04 | Roche Diagnostics Operations, Inc. | Method of detecting native proBNP |
US20070224643A1 (en) | 2006-03-09 | 2007-09-27 | Mcpherson Paul H | Methods and compositions for the diagnosis of diseases of the aorta |
US20080050749A1 (en) | 2006-08-17 | 2008-02-28 | Ildiko Amann-Zalan | Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents |
US20080118924A1 (en) | 2006-05-26 | 2008-05-22 | Buechler Kenneth F | Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases |
US20080171354A1 (en) | 2005-02-17 | 2008-07-17 | Georg Hess | Natriuretic peptide ratio for diagnosing cardiac dysfunctions |
US7421101B2 (en) | 2003-10-02 | 2008-09-02 | Siemens Medical Solutions Usa, Inc. | System and method for local deformable motion analysis |
US7432107B2 (en) | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
US7458936B2 (en) | 2003-03-12 | 2008-12-02 | Siemens Medical Solutions Usa, Inc. | System and method for performing probabilistic classification and decision support using multidimensional medical image databases |
US7507550B2 (en) | 2003-11-28 | 2009-03-24 | Roche Diagnostics Operations, Inc. | Analytical sandwich test for determining NT-proBNP |
US7527939B2 (en) | 2002-11-18 | 2009-05-05 | Nanogen, Inc. | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
US7553937B2 (en) | 2002-08-07 | 2009-06-30 | Bio-Rad Pasteur | Specific antibodies for diagnosing heart failure |
US7608418B2 (en) | 2005-06-07 | 2009-10-27 | Roche Diagnostics Operations, Inc. | NT-proANP and NT-proBNP for diagnosing cardiac diseases |
US20090305265A1 (en) | 2006-04-27 | 2009-12-10 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
US7651679B2 (en) | 2006-09-15 | 2010-01-26 | Roche Diagnostics Operations, Inc. | Biochemical markers for acute pulmonary embolism |
US7655416B2 (en) | 2004-06-15 | 2010-02-02 | Roche Diagnostics Operations, Inc. | Diagnosing risk of cardiovascular complications using natiuretic peptides |
US20100028921A1 (en) | 2006-10-26 | 2010-02-04 | Brahms Aktiengesellschaft | Risk stratification for acute coronary syndrome by means of fragments/partial peptides of provasopressin, especially copeptin or neurophysin ii |
US20100035289A1 (en) | 2006-12-20 | 2010-02-11 | Brahms Aktiengesellschaft | Diagnosis and risk stratification by means of the novel marker ct-proadm |
US20100047835A1 (en) | 2006-10-01 | 2010-02-25 | Brahms Aktiengesellschaft | Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure |
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US7732214B2 (en) | 2006-03-24 | 2010-06-08 | Roche Diagnostics Operations, Inc. | Differentiation of acute and chronic myocardial necrosis in symptomatic patients |
US20100159474A1 (en) | 2008-11-11 | 2010-06-24 | B.R.A.H.M.S. Aktiengesellschaft | Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp |
US7803118B2 (en) | 2004-11-22 | 2010-09-28 | Widemed Ltd. | Detection of heart failure using a photoplethysmograph |
US20100248259A1 (en) | 2007-08-30 | 2010-09-30 | Gerog Hess | Natriuretic peptide/gdf-15 ratio for diagnosis of cardiac disorders |
US20100267062A1 (en) | 2007-09-26 | 2010-10-21 | Norbert Frey | Osteopontin as Novel Prognostic Biomarker for Heart Failure |
US7822627B2 (en) | 2005-05-02 | 2010-10-26 | St Martin Edward | Method and system for generating an echocardiogram report |
US20100279431A1 (en) | 2007-03-06 | 2010-11-04 | Ildiko Amann-Zalan | Use of bnp-type peptides for predicting dialysis need |
US20100285492A1 (en) | 2007-03-08 | 2010-11-11 | Ursula-Henrike Wienhues-Thelen | Use of slim-1 in the assessment of heart failure |
US20100285493A1 (en) | 2007-05-07 | 2010-11-11 | B.R.A.H.M.S. Ag | Method for determining amino-terminal proanp in patients having a cardiac disease or being suspected of developing or having a cardiac disease |
US7892844B2 (en) | 2006-07-28 | 2011-02-22 | Roche Diagnostics Operations, Inc. | Differentiation of cardiac and pulmonary causes of acute shortness of breath |
US7912528B2 (en) | 2003-06-25 | 2011-03-22 | Siemens Medical Solutions Usa, Inc. | Systems and methods for automated diagnosis and decision support for heart related diseases and conditions |
US20110107821A1 (en) | 2008-07-14 | 2011-05-12 | Georg Hess | Multimarker panel for monitoring patients with and without overt heart failure |
US20110111526A1 (en) | 2008-04-09 | 2011-05-12 | B.R.A.H.M.S Gmbh | Pro-endothelin-1 for the prediction of impaired peak oxygen consumption |
US7960123B2 (en) | 2004-07-07 | 2011-06-14 | Roche Diagnostics Operations, Inc. | Multimarker panel based on PIGF for diabetes types 1 and 2 |
US20110139155A1 (en) | 2004-03-31 | 2011-06-16 | Michael Farrell | Methods and apparatus for monitoring the cardiovascular condition of patients with sleep disordered breathing |
US20110152170A1 (en) | 2007-08-03 | 2011-06-23 | B.R.A.H.M.S. Gmbh | Use of Procalcitonin (PCT) in Risk Stratification and Prognosis of Patients with a Primary, Non-Infectious Disease |
US20110165591A1 (en) | 2008-10-17 | 2011-07-07 | Ursula-Henrike Wienhues-Thelen | Use of biglycan in the assessment of heart failure |
US8003396B2 (en) | 2007-10-10 | 2011-08-23 | Roche Diagnostics Operations, Inc. | NT-proBNP/troponin ratio for assessing myocardial dysfunction |
US8036735B2 (en) | 2007-08-08 | 2011-10-11 | Cardiac Pacemakers, Inc. | System for evaluating performance of an implantable medical device |
US20110270530A1 (en) | 2008-12-08 | 2011-11-03 | Seok-Won Lee | Combined natriuretic peptide assays |
US8052611B2 (en) | 2007-03-14 | 2011-11-08 | Cardiac Pacemakers, Inc. | Method and apparatus for management of heart failure hospitalization |
US8090562B2 (en) | 2008-04-18 | 2012-01-03 | Critical Care Diagnostics, Inc. | Predicting risk of major adverse cardiac events |
US8092388B2 (en) | 2007-09-25 | 2012-01-10 | Siemens Medical Solutions Usa, Inc. | Automated view classification with echocardiographic data for gate localization or other purposes |
US20120009610A1 (en) | 2009-04-27 | 2012-01-12 | Ursula-Henrike Wienhues-Thelen | Endostatin as a marker of heart failure |
US20120021431A1 (en) | 2010-02-25 | 2012-01-26 | Toshio Nishikimi | Diagnostic methods using bnp |
US20120028292A1 (en) | 2009-04-30 | 2012-02-02 | Georg Hess | Methods for diagnosing kidney damage associated with heart failure |
US8252544B2 (en) | 2007-03-03 | 2012-08-28 | B.R.A.H.M.S Gmbh | Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for NYHA I patients |
US20120219943A1 (en) | 2011-02-03 | 2012-08-30 | Abbott Laboratories | Methods of prognosis and diagnosis in chronic heart failure |
US20120221310A1 (en) * | 2011-02-28 | 2012-08-30 | The Regents Of The University Of California | System for analyzing physiological signals to predict medical conditions |
US8303505B2 (en) | 2005-12-02 | 2012-11-06 | Abbott Cardiovascular Systems Inc. | Methods and apparatuses for image guided medical procedures |
US8361800B2 (en) | 2006-11-21 | 2013-01-29 | Roche Diagnostics Operations, Inc. | Diagnostic means and methods using troponin T and NT-proBNP |
US8396531B2 (en) | 2007-03-27 | 2013-03-12 | Siemens Medical Solutions Usa, Inc. | System and method for quasi-real-time ventricular measurements from M-mode echocardiogram |
US8422752B2 (en) | 2009-07-03 | 2013-04-16 | Fujifilm Corporation | Diagnosis assisting apparatus, diagnosis assisting method, and storage medium in which a diagnosis assisting program is recorded |
US8444932B2 (en) | 2008-08-13 | 2013-05-21 | Roche Diagnostics Operations, Inc. | D-dimer, troponin, and NT-proBNP for pulmonary embolism |
US8450069B2 (en) | 2009-06-08 | 2013-05-28 | Singulex, Inc. | Highly sensitive biomarker panels |
US8481333B2 (en) | 2011-05-31 | 2013-07-09 | Idexx Laboratories, Inc. | Detection of degradation products of feline NT-proBNP |
US8486706B2 (en) | 2008-05-21 | 2013-07-16 | Roche Diagnostics Operations, Inc. | L-FABP, natriuretic peptides, and cardiac troponins in subjects in need of cardiac therapy |
US8486652B2 (en) | 2009-01-30 | 2013-07-16 | Bio-Rad Innovations | Method for the in vitro diagnosis of stroke |
US8524463B2 (en) | 2006-12-22 | 2013-09-03 | B.R.A.H.M.S Gmbh | Diagnosis and risk classification of acute coronary syndrome by means of CT-proET-1 in combination with NT-proBNP |
US20130238363A1 (en) * | 2010-11-26 | 2013-09-12 | Hitachi, Ltd. | Medical examination assistance system and method of assisting medical examination |
US8602996B2 (en) | 2010-06-01 | 2013-12-10 | Cardiac Pacemakers, Inc. | Integrating device-based sensors and bedside biomarker assays to detect worsening heart failure |
US20140072959A1 (en) | 2012-09-12 | 2014-03-13 | Force Diagnostics, Inc. | Rapid tests for insurance underwriting |
US8691587B2 (en) | 2008-04-30 | 2014-04-08 | Roche Diagnostics Operations, Inc. | Use of SFRP-3 in the assessment of heart failure |
US8744152B2 (en) | 2010-06-19 | 2014-06-03 | International Business Machines Corporation | Echocardiogram view classification using edge filtered scale-invariant motion features |
US8778699B2 (en) | 2010-08-04 | 2014-07-15 | Idexx Laboratories, Inc. | Detection of degradation products of canine NT-proBNP |
US20140206632A1 (en) | 2013-01-22 | 2014-07-24 | Singulex, Inc. | Endothelin in the Diagnosis of Cardiac Disease |
US8795975B2 (en) | 2010-11-29 | 2014-08-05 | Alere San Diego, Inc. | Methods and compositions for diagnosis and risk prediction in heart failure |
US20140233818A1 (en) | 2013-02-19 | 2014-08-21 | General Electric Company | Methods and systems for segmentation in echocardiography |
US20140274793A1 (en) | 2011-12-01 | 2014-09-18 | Roche Diagnostics Operations, Inc. | NT-proANP AND NT-proBNP FOR THE DIAGNOSIS OF STROKE |
US20140273273A1 (en) | 2012-11-01 | 2014-09-18 | Christie Mitchell Ballantyne | Biomarkers to improve prediction of heart failure risk |
US20140364366A1 (en) | 2011-10-10 | 2014-12-11 | Zensun (Shanghai) Science & Technology Ltd. | Compositions and methods for treating heart failure |
US8917917B2 (en) | 2009-06-26 | 2014-12-23 | International Business Machines Corporation | Cardiac view recognition and disease recognition |
US9012151B2 (en) | 2006-11-09 | 2015-04-21 | B.R.A.H.M.S. Gmbh | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin |
US20150119271A1 (en) | 2012-04-26 | 2015-04-30 | B.R.A.H.M.S. Gmbh | Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope |
US20150141826A1 (en) | 2013-11-16 | 2015-05-21 | International Business Machines Corporation | Prediction of diseases based on analysis of medical exam and/or test workflow |
US20150169840A1 (en) | 2011-08-05 | 2015-06-18 | Alere San Diego, Inc. | Methods and compositions for monitoring heart failure |
US20150164468A1 (en) | 2013-12-13 | 2015-06-18 | Institute For Basic Science | Apparatus and method for processing echocardiogram using navier-stokes equation |
US20150185230A1 (en) | 2012-09-12 | 2015-07-02 | Roche Diagnostics Operations, Inc | Identification of patients with abnormal fractional shortening |
US20150199491A1 (en) | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
US9103839B2 (en) | 2007-03-07 | 2015-08-11 | Biomedica Medizinprodukte Gmbh & Co Kg | Method of determining equine NT-proBNP |
US20150233945A1 (en) | 2012-11-09 | 2015-08-20 | Roche Diagnostics Operations, Inc. | NTproBNP AND cTnT BASED THERAPY GUIDANCE IN HEART FAILURE |
US20160003819A1 (en) | 2012-09-12 | 2016-01-07 | Force Diagnostics, Inc. | Rapid tests for insurance underwriting |
US9261516B2 (en) | 2007-05-08 | 2016-02-16 | B.R.A.H.M.S Gmbh | Diagnosis and risk stratification using NT-proET-1 |
US9280819B2 (en) | 2013-08-26 | 2016-03-08 | International Business Machines Corporation | Image segmentation techniques |
US20160146836A1 (en) | 2013-07-29 | 2016-05-26 | Roche Diagnostics Operations, Inc. | Use of alpha-crystallin b (cryab) in the assessment of heart failure |
US20160199022A1 (en) | 2015-01-13 | 2016-07-14 | Samsung Medison Co., Ltd. | Ultrasound diagnosis apparatus and method of operating the same |
US20160203288A1 (en) | 2012-06-18 | 2016-07-14 | The Research Foundation For The State University Of New York | Systems and Methods for Identifying Historical Vasculature Cases |
US20160206250A1 (en) | 2014-07-14 | 2016-07-21 | Medtronic, Inc. | Using biomarker information for heart failure risk computation |
US20170010283A1 (en) | 2014-03-26 | 2017-01-12 | Roche Diagnostics Operations, Inc. | Igfbp7 for diagnosing diastolic dysfunction |
WO2017009812A1 (en) | 2015-07-15 | 2017-01-19 | Oxford University Innovation Limited | System and method for structures detection and multi-class image categorization in medical imaging |
US9605068B2 (en) | 2004-09-08 | 2017-03-28 | The Antibody Lab Gmbh | Determining feline proBNP |
US9753039B2 (en) | 2012-04-12 | 2017-09-05 | B.R.A.H.M.S Gmbh | Prognosis of adverse events in patients with suspected chronic heart failure |
US20170285049A1 (en) | 2014-09-01 | 2017-10-05 | Metanomics Gmbh | Means and Methods for Diagnosing Heart Failure in a Subject |
WO2017181288A1 (en) | 2016-04-21 | 2017-10-26 | The University Of British Columbia | Echocardiographic image analysis |
US20170322225A1 (en) | 2014-10-22 | 2017-11-09 | Hoffmann-La Roche Inc. | Biomarkers and methods of prediction |
WO2017205836A1 (en) | 2016-05-26 | 2017-11-30 | Icahn School Of Medicine At Mount Sinai | Systems and methods for categorization |
US9842390B2 (en) | 2015-02-06 | 2017-12-12 | International Business Machines Corporation | Automatic ground truth generation for medical image collections |
US20170367604A1 (en) | 2013-11-08 | 2017-12-28 | Spangler Scientific Llc | Non-invasive prediction of risk for sudden cardiac death |
US9918023B2 (en) | 2010-04-23 | 2018-03-13 | Flir Systems, Inc. | Segmented focal plane array architecture |
US9924116B2 (en) | 2014-08-05 | 2018-03-20 | Seek Thermal, Inc. | Time based offset correction for imaging systems and adaptive calibration control |
US9930324B2 (en) | 2014-08-05 | 2018-03-27 | Seek Thermal, Inc. | Time based offset correction for imaging systems |
US20180107787A1 (en) * | 2016-10-17 | 2018-04-19 | International Business Machines Corporation | Workflow for automatic measurement of doppler pipeline |
US20180108125A1 (en) * | 2016-10-17 | 2018-04-19 | International Business Machines Corporation | Automatic detection of disease from analysis of echocardiographer findings in echocardiogram videos |
US20180103914A1 (en) | 2016-10-17 | 2018-04-19 | International Business Machines Corporation | Automatic extraction of disease-specific features from doppler images |
US20180103931A1 (en) * | 2016-10-17 | 2018-04-19 | International Business Machines Corporation | Detection of valve disease from analysis of doppler waveforms exploiting the echocardiography annotations |
US20180107801A1 (en) * | 2016-10-17 | 2018-04-19 | International Business Machines Corporation | Automatic disease detection from unstructured textual reports |
US20180119222A1 (en) | 2015-05-08 | 2018-05-03 | Agency For Science, Technology And Research | Method for diagnosis and prognosis of chronic heart failure |
US20180125820A1 (en) | 2015-05-11 | 2018-05-10 | Novartis Ag | Sacubitril-valsartan dosage regimen for treating heart failure |
US9984283B2 (en) | 2015-02-14 | 2018-05-29 | The Trustees Of The University Of Pennsylvania | Methods, systems, and computer readable media for automated detection of abnormalities in medical images |
US20180204364A1 (en) | 2017-01-13 | 2018-07-19 | Flir Systems, Inc. | High visibility overlay systems and methods |
US10033944B2 (en) | 2009-03-02 | 2018-07-24 | Flir Systems, Inc. | Time spaced infrared image enhancement |
US10044946B2 (en) | 2009-06-03 | 2018-08-07 | Flir Systems Ab | Facilitating analysis and interpretation of associated visible light and infrared (IR) image information |
US20180265923A1 (en) | 2015-09-15 | 2018-09-20 | Luxembourg Institute Of Health (Lih) | Biomarkers for Heart Failure |
US20180266886A1 (en) | 2015-12-09 | 2018-09-20 | Flir Systems, Inc. | Airborne inspection systems and methods |
US10091439B2 (en) | 2009-06-03 | 2018-10-02 | Flir Systems, Inc. | Imager with array of multiple infrared imaging modules |
US10114028B2 (en) | 2012-03-20 | 2018-10-30 | Upstream Medical Technologies Limited | Biomarkers for pneumonia and acute decompensated heart failure |
US10122944B2 (en) | 2011-06-10 | 2018-11-06 | Flir Systems, Inc. | Low power and small form factor infrared imaging |
US20180330474A1 (en) | 2016-01-16 | 2018-11-15 | Flir Systems, Inc. | Systems and methods for image super-resolution using iterative collaborative filtering |
US10143390B2 (en) * | 2016-05-02 | 2018-12-04 | Pie Medical Imaging B.V. | Method and apparatus to automatically determine the relationship between data |
US20190011463A1 (en) | 2015-12-28 | 2019-01-10 | Upstream Medical Technologies Limited | Diagnosis of unstable angina |
US10182195B2 (en) | 2014-09-23 | 2019-01-15 | Flir Systems, Inc. | Protective window for an infrared sensor array |
US10192540B2 (en) | 2014-02-20 | 2019-01-29 | FLIR Belgium BVBA | Coordinated route distribution systems and methods |
US20190064191A1 (en) | 2016-02-04 | 2019-02-28 | Metanomics Gmbh | Means and methods for differentiating between heart failure and pulmonary disease in a subject |
US10230909B2 (en) | 2014-09-23 | 2019-03-12 | Flir Systems, Inc. | Modular split-processing infrared imaging system |
US10230910B2 (en) | 2011-06-10 | 2019-03-12 | Flir Systems, Inc. | Infrared camera system architectures |
US10234462B2 (en) | 2009-07-27 | 2019-03-19 | Roche Diagnostics Operations, Inc. | Use of mimecan in the assessment of heart failure |
US10244190B2 (en) | 2009-03-02 | 2019-03-26 | Flir Systems, Inc. | Compact multi-spectrum imaging with fusion |
US10249032B2 (en) | 2010-04-23 | 2019-04-02 | Flir Systems Ab | Infrared resolution and contrast enhancement with fusion |
US10250822B2 (en) | 2011-06-10 | 2019-04-02 | Flir Systems, Inc. | Wearable apparatus with integrated infrared imaging module |
US10303844B2 (en) | 2012-08-21 | 2019-05-28 | Critical Care Diagnostics, Inc. | Multimarker risk stratification |
US20190187154A1 (en) | 2017-12-15 | 2019-06-20 | Jana Care, Inc. | Biomedical measuring devices, systems, and methods for measuring peptide concentration to monitor a condition |
US10338800B2 (en) | 2014-02-21 | 2019-07-02 | FLIR Belgium BVBA | Enhanced pilot display systems and methods |
US10425603B2 (en) | 2015-03-06 | 2019-09-24 | Flir Systems, Inc. | Anomalous pixel detection |
US20190298303A1 (en) | 2016-06-17 | 2019-10-03 | Koninklijke Philips N.V. | System and method for determining hemodynamic parameters of a patient |
US10436887B2 (en) | 2014-05-30 | 2019-10-08 | Flir Systems, Inc. | Transmission signal shaping systems and methods |
US20190325566A1 (en) | 2017-01-03 | 2019-10-24 | FUR Systems, Inc. | Image noise reduction using spectral transforms |
US20190335118A1 (en) | 2017-01-13 | 2019-10-31 | Flir Systems, Inc. | Pixel readout with partitioned analog-to-digital conversion systems and methods |
US20190342480A1 (en) | 2017-01-26 | 2019-11-07 | Flir Systems, Inc. | Infrared imaging in multiple imaging modes systems and methods |
US10488422B2 (en) | 2007-01-25 | 2019-11-26 | Roche Diagnostics Operations, Inc. | Use of IGFBP-7 in the assessment of heart failure |
US20190359300A1 (en) | 2014-12-31 | 2019-11-28 | FLIR Belgium BVBA | Perimeter ranging sensor systems and methods |
US20190369117A1 (en) | 2017-02-13 | 2019-12-05 | Roche Diagnostics Operations, Inc. | Antibodies recognizing generic variants |
US10509044B2 (en) | 2014-05-08 | 2019-12-17 | University Of Maryland, Baltimore | Methods for assessing differential risk for developing heart failure |
US20190392944A1 (en) * | 2018-06-22 | 2019-12-26 | General Electric Company | Method and workstations for a diagnostic support system |
US20190391162A1 (en) | 2012-05-18 | 2019-12-26 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
US20200005440A1 (en) | 2017-03-15 | 2020-01-02 | Flir Systems, Inc. | Systems and methods for reducing low-frequency non-uniformity in images |
US10557858B2 (en) | 2014-10-29 | 2020-02-11 | Roche Diagnostics Operations, Inc. | Biomarkers for risk prediction of mortality |
US10598550B2 (en) | 2017-02-17 | 2020-03-24 | Flir Systems, Inc. | Radiometric correction and alignment techniques for thermal imager with non-contact temperature sensor |
US20200107818A1 (en) * | 2018-10-08 | 2020-04-09 | General Electric Company | Ultrasound cardiac doppler study automation |
US10623667B2 (en) | 2015-09-18 | 2020-04-14 | Flir Systems, Inc. | High dynamic range radiometric thermal video over low bitrate interface |
US20200113544A1 (en) * | 2018-10-15 | 2020-04-16 | General Electric Company | Method and system for enhanced visualization of ultrasound probe positioning feedback |
US10631828B1 (en) * | 2018-12-11 | 2020-04-28 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and the diagnosis, prediction and prognosis of heart disease |
US20200141807A1 (en) | 2017-06-03 | 2020-05-07 | Flir Systems, Inc. | Extensible architecture for surveillance and targetng imaging systems and methods |
US20200185084A1 (en) * | 2018-12-11 | 2020-06-11 | International Business Machines Corporation | Automated Normality Scoring of Echocardiograms |
US20200193652A1 (en) | 2017-01-13 | 2020-06-18 | Flir Systems, Inc. | High visibility overlay systems and methods |
US20200226757A1 (en) * | 2018-12-11 | 2020-07-16 | Eko.Ai Pte. Ltd. | Training neural networks of an automatic clinical workflow that recognizes and analyzes 2d and doppler modality echocardiogram images |
US10803553B2 (en) | 2016-01-08 | 2020-10-13 | Flir Systems, Inc. | Systems and methods for image resolution enhancement |
US20200327646A1 (en) | 2017-12-29 | 2020-10-15 | Flir Systems, Inc. | Point cloud denoising systems and methods |
US20200401143A1 (en) | 2017-06-16 | 2020-12-24 | FLIR Belgium BVBA | Ultrasonic perimeter ranging sensor systems and methods |
US20200397313A1 (en) * | 2017-10-06 | 2020-12-24 | Mayo Foundation For Medical Education And Research | Ecg-based cardiac ejection-fraction screening |
US10909660B2 (en) | 2017-02-15 | 2021-02-02 | Flir Systems, Inc. | Systems and methods for efficient enhanced image filtering by collaborative sharpening in similarity domain |
US20210052252A1 (en) * | 2018-12-11 | 2021-02-25 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and ai recognition of 2d and doppler modality echocardiogram images |
US10937140B2 (en) | 2016-09-29 | 2021-03-02 | Flir Systems, Inc. | Fail-safe detection using thermal imaging analytics |
US20210080260A1 (en) | 2019-09-16 | 2021-03-18 | FLIR Belgium BVBA | Imaging for navigation systems and methods |
US10962420B2 (en) | 2017-12-29 | 2021-03-30 | Flir Systems, Inc. | Pulse detection and imaging systems and methods |
US10986288B2 (en) | 2017-07-27 | 2021-04-20 | Flir Systems, Inc. | Flat field correction systems and methods for infrared cameras |
US10983206B2 (en) | 2017-11-07 | 2021-04-20 | FLIR Belgium BVBA | Low cost high precision GNSS systems and methods |
US10986338B2 (en) | 2016-06-24 | 2021-04-20 | Flir Systems, Inc. | Thermal-image based video compression systems and methods |
US10996542B2 (en) | 2012-12-31 | 2021-05-04 | Flir Systems, Inc. | Infrared imaging system shutter assembly with integrated thermister |
US11010878B2 (en) | 2016-11-04 | 2021-05-18 | Flir Systems, Inc. | Dynamic range compression for thermal video |
US20210219922A1 (en) * | 2017-11-02 | 2021-07-22 | Koninklijke Philips N.V. | A method and apparatus for analysing echocardiograms |
US20210219944A1 (en) * | 2018-05-31 | 2021-07-22 | Mayo Foundation For Medical Education And Research | Systems and Media for Automatically Diagnosing Thyroid Nodules |
US20210259664A1 (en) * | 2018-12-11 | 2021-08-26 | Eko.Ai Pte. Ltd. | Artificial intelligence (ai) recognition of echocardiogram images to enhance a mobile ultrasound device |
US20210264238A1 (en) * | 2018-12-11 | 2021-08-26 | Eko.Ai Pte. Ltd. | Artificial intelligence (ai)-based guidance for an ultrasound device to improve capture of echo image views |
US20230221878A1 (en) * | 2020-12-31 | 2023-07-13 | Pure Storage, Inc. | Selectable Write Paths With Different Formatted Data |
-
2021
- 2021-03-31 US US17/219,670 patent/US12001939B2/en active Active
Patent Citations (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6514207B2 (en) | 2000-04-13 | 2003-02-04 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for processing echocardiogram video images |
US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
US20040077027A1 (en) | 2002-07-11 | 2004-04-22 | Leong Ng | Assays and kits for detecting and monitoring heart disease |
US7553937B2 (en) | 2002-08-07 | 2009-06-30 | Bio-Rad Pasteur | Specific antibodies for diagnosing heart failure |
US20040133083A1 (en) | 2002-11-13 | 2004-07-08 | Siemens Corporate Research Inc. | System and method for real-time feature sensitivity analysis based on contextual information |
US7087018B2 (en) | 2002-11-13 | 2006-08-08 | Siemens Medical Solutions Usa, Inc. | System and method for real-time feature sensitivity analysis based on contextual information |
US20050287613A1 (en) | 2002-11-18 | 2005-12-29 | George Jackowski | Polyclonal-polyclonal ELISA assay for detecting N-terminus-proBNP |
US20040096919A1 (en) | 2002-11-18 | 2004-05-20 | Michelle Davey | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
US7135329B2 (en) | 2002-11-18 | 2006-11-14 | Princeton Biomeditech Corporation | Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients |
US7527939B2 (en) | 2002-11-18 | 2009-05-05 | Nanogen, Inc. | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US8060178B2 (en) | 2003-03-12 | 2011-11-15 | Siemens Medical Solutions Usa, Inc. | System and method for performing probabilistic classification and decision support using multidimensional medical image databases |
US7458936B2 (en) | 2003-03-12 | 2008-12-02 | Siemens Medical Solutions Usa, Inc. | System and method for performing probabilistic classification and decision support using multidimensional medical image databases |
US7264938B2 (en) | 2003-05-12 | 2007-09-04 | Roche Diagnostics Operations, Inc. | Method of detecting native proBNP |
US7912528B2 (en) | 2003-06-25 | 2011-03-22 | Siemens Medical Solutions Usa, Inc. | Systems and methods for automated diagnosis and decision support for heart related diseases and conditions |
US20070141634A1 (en) | 2003-06-30 | 2007-06-21 | Orion Diagnostica Oy Body Corporate | Assay |
US20050074088A1 (en) * | 2003-08-27 | 2005-04-07 | Matsushita Electric Industrial Co., Ltd. | X-ray inspection apparatus and X-ray inspection method |
US7421101B2 (en) | 2003-10-02 | 2008-09-02 | Siemens Medical Solutions Usa, Inc. | System and method for local deformable motion analysis |
US20060286681A1 (en) | 2003-11-07 | 2006-12-21 | Hans-Peter Lehmann | Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease |
US7507550B2 (en) | 2003-11-28 | 2009-03-24 | Roche Diagnostics Operations, Inc. | Analytical sandwich test for determining NT-proBNP |
US20050239138A1 (en) | 2004-03-15 | 2005-10-27 | Georg Hess | Use of cardiac hormones to assess risk of cardiovascular complication from volume overload |
US20110139155A1 (en) | 2004-03-31 | 2011-06-16 | Michael Farrell | Methods and apparatus for monitoring the cardiovascular condition of patients with sleep disordered breathing |
US7655416B2 (en) | 2004-06-15 | 2010-02-02 | Roche Diagnostics Operations, Inc. | Diagnosing risk of cardiovascular complications using natiuretic peptides |
US20070015208A1 (en) | 2004-07-07 | 2007-01-18 | Roche Diagnostics Operations, Inc. | Multimarker panel for diabetes type 1 and 2 |
US7960123B2 (en) | 2004-07-07 | 2011-06-14 | Roche Diagnostics Operations, Inc. | Multimarker panel based on PIGF for diabetes types 1 and 2 |
US9605068B2 (en) | 2004-09-08 | 2017-03-28 | The Antibody Lab Gmbh | Determining feline proBNP |
US7803118B2 (en) | 2004-11-22 | 2010-09-28 | Widemed Ltd. | Detection of heart failure using a photoplethysmograph |
US7432107B2 (en) | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
US20060166303A1 (en) | 2005-01-24 | 2006-07-27 | Eberhard Spanuth | Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs |
US20080171354A1 (en) | 2005-02-17 | 2008-07-17 | Georg Hess | Natriuretic peptide ratio for diagnosing cardiac dysfunctions |
US7822627B2 (en) | 2005-05-02 | 2010-10-26 | St Martin Edward | Method and system for generating an echocardiogram report |
US20060264764A1 (en) | 2005-05-18 | 2006-11-23 | Alejandro Ortiz-Burgos | System and method for non-invasively determining a left ventricular end-diastolic pressure |
US7608418B2 (en) | 2005-06-07 | 2009-10-27 | Roche Diagnostics Operations, Inc. | NT-proANP and NT-proBNP for diagnosing cardiac diseases |
US8303505B2 (en) | 2005-12-02 | 2012-11-06 | Abbott Cardiovascular Systems Inc. | Methods and apparatuses for image guided medical procedures |
US20070224643A1 (en) | 2006-03-09 | 2007-09-27 | Mcpherson Paul H | Methods and compositions for the diagnosis of diseases of the aorta |
US7732214B2 (en) | 2006-03-24 | 2010-06-08 | Roche Diagnostics Operations, Inc. | Differentiation of acute and chronic myocardial necrosis in symptomatic patients |
US20090305265A1 (en) | 2006-04-27 | 2009-12-10 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
US20080118924A1 (en) | 2006-05-26 | 2008-05-22 | Buechler Kenneth F | Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases |
US7892844B2 (en) | 2006-07-28 | 2011-02-22 | Roche Diagnostics Operations, Inc. | Differentiation of cardiac and pulmonary causes of acute shortness of breath |
US20080050749A1 (en) | 2006-08-17 | 2008-02-28 | Ildiko Amann-Zalan | Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents |
US7651679B2 (en) | 2006-09-15 | 2010-01-26 | Roche Diagnostics Operations, Inc. | Biochemical markers for acute pulmonary embolism |
US20100047835A1 (en) | 2006-10-01 | 2010-02-25 | Brahms Aktiengesellschaft | Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure |
US20100028921A1 (en) | 2006-10-26 | 2010-02-04 | Brahms Aktiengesellschaft | Risk stratification for acute coronary syndrome by means of fragments/partial peptides of provasopressin, especially copeptin or neurophysin ii |
US9012151B2 (en) | 2006-11-09 | 2015-04-21 | B.R.A.H.M.S. Gmbh | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin |
US8361800B2 (en) | 2006-11-21 | 2013-01-29 | Roche Diagnostics Operations, Inc. | Diagnostic means and methods using troponin T and NT-proBNP |
US20100035289A1 (en) | 2006-12-20 | 2010-02-11 | Brahms Aktiengesellschaft | Diagnosis and risk stratification by means of the novel marker ct-proadm |
US8524463B2 (en) | 2006-12-22 | 2013-09-03 | B.R.A.H.M.S Gmbh | Diagnosis and risk classification of acute coronary syndrome by means of CT-proET-1 in combination with NT-proBNP |
US10488422B2 (en) | 2007-01-25 | 2019-11-26 | Roche Diagnostics Operations, Inc. | Use of IGFBP-7 in the assessment of heart failure |
US8252544B2 (en) | 2007-03-03 | 2012-08-28 | B.R.A.H.M.S Gmbh | Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for NYHA I patients |
US20100279431A1 (en) | 2007-03-06 | 2010-11-04 | Ildiko Amann-Zalan | Use of bnp-type peptides for predicting dialysis need |
US9103839B2 (en) | 2007-03-07 | 2015-08-11 | Biomedica Medizinprodukte Gmbh & Co Kg | Method of determining equine NT-proBNP |
US20100285492A1 (en) | 2007-03-08 | 2010-11-11 | Ursula-Henrike Wienhues-Thelen | Use of slim-1 in the assessment of heart failure |
US8052611B2 (en) | 2007-03-14 | 2011-11-08 | Cardiac Pacemakers, Inc. | Method and apparatus for management of heart failure hospitalization |
US8396531B2 (en) | 2007-03-27 | 2013-03-12 | Siemens Medical Solutions Usa, Inc. | System and method for quasi-real-time ventricular measurements from M-mode echocardiogram |
US20100285493A1 (en) | 2007-05-07 | 2010-11-11 | B.R.A.H.M.S. Ag | Method for determining amino-terminal proanp in patients having a cardiac disease or being suspected of developing or having a cardiac disease |
US9261516B2 (en) | 2007-05-08 | 2016-02-16 | B.R.A.H.M.S Gmbh | Diagnosis and risk stratification using NT-proET-1 |
US20110152170A1 (en) | 2007-08-03 | 2011-06-23 | B.R.A.H.M.S. Gmbh | Use of Procalcitonin (PCT) in Risk Stratification and Prognosis of Patients with a Primary, Non-Infectious Disease |
US8036735B2 (en) | 2007-08-08 | 2011-10-11 | Cardiac Pacemakers, Inc. | System for evaluating performance of an implantable medical device |
US20100248259A1 (en) | 2007-08-30 | 2010-09-30 | Gerog Hess | Natriuretic peptide/gdf-15 ratio for diagnosis of cardiac disorders |
US8092388B2 (en) | 2007-09-25 | 2012-01-10 | Siemens Medical Solutions Usa, Inc. | Automated view classification with echocardiographic data for gate localization or other purposes |
US20100267062A1 (en) | 2007-09-26 | 2010-10-21 | Norbert Frey | Osteopontin as Novel Prognostic Biomarker for Heart Failure |
US8003396B2 (en) | 2007-10-10 | 2011-08-23 | Roche Diagnostics Operations, Inc. | NT-proBNP/troponin ratio for assessing myocardial dysfunction |
US20110111526A1 (en) | 2008-04-09 | 2011-05-12 | B.R.A.H.M.S Gmbh | Pro-endothelin-1 for the prediction of impaired peak oxygen consumption |
US8090562B2 (en) | 2008-04-18 | 2012-01-03 | Critical Care Diagnostics, Inc. | Predicting risk of major adverse cardiac events |
US8691587B2 (en) | 2008-04-30 | 2014-04-08 | Roche Diagnostics Operations, Inc. | Use of SFRP-3 in the assessment of heart failure |
US8486706B2 (en) | 2008-05-21 | 2013-07-16 | Roche Diagnostics Operations, Inc. | L-FABP, natriuretic peptides, and cardiac troponins in subjects in need of cardiac therapy |
US20110107821A1 (en) | 2008-07-14 | 2011-05-12 | Georg Hess | Multimarker panel for monitoring patients with and without overt heart failure |
US8444932B2 (en) | 2008-08-13 | 2013-05-21 | Roche Diagnostics Operations, Inc. | D-dimer, troponin, and NT-proBNP for pulmonary embolism |
US20110165591A1 (en) | 2008-10-17 | 2011-07-07 | Ursula-Henrike Wienhues-Thelen | Use of biglycan in the assessment of heart failure |
US20100159474A1 (en) | 2008-11-11 | 2010-06-24 | B.R.A.H.M.S. Aktiengesellschaft | Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp |
US20110270530A1 (en) | 2008-12-08 | 2011-11-03 | Seok-Won Lee | Combined natriuretic peptide assays |
US8486652B2 (en) | 2009-01-30 | 2013-07-16 | Bio-Rad Innovations | Method for the in vitro diagnosis of stroke |
US10244190B2 (en) | 2009-03-02 | 2019-03-26 | Flir Systems, Inc. | Compact multi-spectrum imaging with fusion |
US10033944B2 (en) | 2009-03-02 | 2018-07-24 | Flir Systems, Inc. | Time spaced infrared image enhancement |
US20120009610A1 (en) | 2009-04-27 | 2012-01-12 | Ursula-Henrike Wienhues-Thelen | Endostatin as a marker of heart failure |
US20120028292A1 (en) | 2009-04-30 | 2012-02-02 | Georg Hess | Methods for diagnosing kidney damage associated with heart failure |
US10044946B2 (en) | 2009-06-03 | 2018-08-07 | Flir Systems Ab | Facilitating analysis and interpretation of associated visible light and infrared (IR) image information |
US20190141261A1 (en) | 2009-06-03 | 2019-05-09 | Flir Systems, Inc. | Imager with array of multiple infrared imaging modules |
US10091439B2 (en) | 2009-06-03 | 2018-10-02 | Flir Systems, Inc. | Imager with array of multiple infrared imaging modules |
US8450069B2 (en) | 2009-06-08 | 2013-05-28 | Singulex, Inc. | Highly sensitive biomarker panels |
US8917917B2 (en) | 2009-06-26 | 2014-12-23 | International Business Machines Corporation | Cardiac view recognition and disease recognition |
US8422752B2 (en) | 2009-07-03 | 2013-04-16 | Fujifilm Corporation | Diagnosis assisting apparatus, diagnosis assisting method, and storage medium in which a diagnosis assisting program is recorded |
US10234462B2 (en) | 2009-07-27 | 2019-03-19 | Roche Diagnostics Operations, Inc. | Use of mimecan in the assessment of heart failure |
US20120021431A1 (en) | 2010-02-25 | 2012-01-26 | Toshio Nishikimi | Diagnostic methods using bnp |
US10249032B2 (en) | 2010-04-23 | 2019-04-02 | Flir Systems Ab | Infrared resolution and contrast enhancement with fusion |
US20190228513A1 (en) | 2010-04-23 | 2019-07-25 | Flir Systems Ab | Infrared resolution and contrast enhancement with fusion |
US9918023B2 (en) | 2010-04-23 | 2018-03-13 | Flir Systems, Inc. | Segmented focal plane array architecture |
US20180205893A1 (en) | 2010-04-23 | 2018-07-19 | Flir Systems, Inc. | Segmented focal plane array architecture |
US8602996B2 (en) | 2010-06-01 | 2013-12-10 | Cardiac Pacemakers, Inc. | Integrating device-based sensors and bedside biomarker assays to detect worsening heart failure |
US8744152B2 (en) | 2010-06-19 | 2014-06-03 | International Business Machines Corporation | Echocardiogram view classification using edge filtered scale-invariant motion features |
US8778699B2 (en) | 2010-08-04 | 2014-07-15 | Idexx Laboratories, Inc. | Detection of degradation products of canine NT-proBNP |
US20130238363A1 (en) * | 2010-11-26 | 2013-09-12 | Hitachi, Ltd. | Medical examination assistance system and method of assisting medical examination |
US8795975B2 (en) | 2010-11-29 | 2014-08-05 | Alere San Diego, Inc. | Methods and compositions for diagnosis and risk prediction in heart failure |
US20120219943A1 (en) | 2011-02-03 | 2012-08-30 | Abbott Laboratories | Methods of prognosis and diagnosis in chronic heart failure |
US20120221310A1 (en) * | 2011-02-28 | 2012-08-30 | The Regents Of The University Of California | System for analyzing physiological signals to predict medical conditions |
US8481333B2 (en) | 2011-05-31 | 2013-07-09 | Idexx Laboratories, Inc. | Detection of degradation products of feline NT-proBNP |
US10230910B2 (en) | 2011-06-10 | 2019-03-12 | Flir Systems, Inc. | Infrared camera system architectures |
US10250822B2 (en) | 2011-06-10 | 2019-04-02 | Flir Systems, Inc. | Wearable apparatus with integrated infrared imaging module |
US10122944B2 (en) | 2011-06-10 | 2018-11-06 | Flir Systems, Inc. | Low power and small form factor infrared imaging |
US20150169840A1 (en) | 2011-08-05 | 2015-06-18 | Alere San Diego, Inc. | Methods and compositions for monitoring heart failure |
US20140364366A1 (en) | 2011-10-10 | 2014-12-11 | Zensun (Shanghai) Science & Technology Ltd. | Compositions and methods for treating heart failure |
US20140274793A1 (en) | 2011-12-01 | 2014-09-18 | Roche Diagnostics Operations, Inc. | NT-proANP AND NT-proBNP FOR THE DIAGNOSIS OF STROKE |
US10114028B2 (en) | 2012-03-20 | 2018-10-30 | Upstream Medical Technologies Limited | Biomarkers for pneumonia and acute decompensated heart failure |
US9753039B2 (en) | 2012-04-12 | 2017-09-05 | B.R.A.H.M.S Gmbh | Prognosis of adverse events in patients with suspected chronic heart failure |
US20150119271A1 (en) | 2012-04-26 | 2015-04-30 | B.R.A.H.M.S. Gmbh | Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope |
US20190391162A1 (en) | 2012-05-18 | 2019-12-26 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
US20160203288A1 (en) | 2012-06-18 | 2016-07-14 | The Research Foundation For The State University Of New York | Systems and Methods for Identifying Historical Vasculature Cases |
US10303844B2 (en) | 2012-08-21 | 2019-05-28 | Critical Care Diagnostics, Inc. | Multimarker risk stratification |
US20160003819A1 (en) | 2012-09-12 | 2016-01-07 | Force Diagnostics, Inc. | Rapid tests for insurance underwriting |
US20140072959A1 (en) | 2012-09-12 | 2014-03-13 | Force Diagnostics, Inc. | Rapid tests for insurance underwriting |
US20150185230A1 (en) | 2012-09-12 | 2015-07-02 | Roche Diagnostics Operations, Inc | Identification of patients with abnormal fractional shortening |
US20140273273A1 (en) | 2012-11-01 | 2014-09-18 | Christie Mitchell Ballantyne | Biomarkers to improve prediction of heart failure risk |
US20150233945A1 (en) | 2012-11-09 | 2015-08-20 | Roche Diagnostics Operations, Inc. | NTproBNP AND cTnT BASED THERAPY GUIDANCE IN HEART FAILURE |
US10996542B2 (en) | 2012-12-31 | 2021-05-04 | Flir Systems, Inc. | Infrared imaging system shutter assembly with integrated thermister |
US20140206632A1 (en) | 2013-01-22 | 2014-07-24 | Singulex, Inc. | Endothelin in the Diagnosis of Cardiac Disease |
US20140233818A1 (en) | 2013-02-19 | 2014-08-21 | General Electric Company | Methods and systems for segmentation in echocardiography |
US20160146836A1 (en) | 2013-07-29 | 2016-05-26 | Roche Diagnostics Operations, Inc. | Use of alpha-crystallin b (cryab) in the assessment of heart failure |
US9280819B2 (en) | 2013-08-26 | 2016-03-08 | International Business Machines Corporation | Image segmentation techniques |
US20170367604A1 (en) | 2013-11-08 | 2017-12-28 | Spangler Scientific Llc | Non-invasive prediction of risk for sudden cardiac death |
US20150141826A1 (en) | 2013-11-16 | 2015-05-21 | International Business Machines Corporation | Prediction of diseases based on analysis of medical exam and/or test workflow |
US20150164468A1 (en) | 2013-12-13 | 2015-06-18 | Institute For Basic Science | Apparatus and method for processing echocardiogram using navier-stokes equation |
US20150199491A1 (en) | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
US10192540B2 (en) | 2014-02-20 | 2019-01-29 | FLIR Belgium BVBA | Coordinated route distribution systems and methods |
US10338800B2 (en) | 2014-02-21 | 2019-07-02 | FLIR Belgium BVBA | Enhanced pilot display systems and methods |
US20170010283A1 (en) | 2014-03-26 | 2017-01-12 | Roche Diagnostics Operations, Inc. | Igfbp7 for diagnosing diastolic dysfunction |
US10509044B2 (en) | 2014-05-08 | 2019-12-17 | University Of Maryland, Baltimore | Methods for assessing differential risk for developing heart failure |
US10436887B2 (en) | 2014-05-30 | 2019-10-08 | Flir Systems, Inc. | Transmission signal shaping systems and methods |
US20160206250A1 (en) | 2014-07-14 | 2016-07-21 | Medtronic, Inc. | Using biomarker information for heart failure risk computation |
US9930324B2 (en) | 2014-08-05 | 2018-03-27 | Seek Thermal, Inc. | Time based offset correction for imaging systems |
US9924116B2 (en) | 2014-08-05 | 2018-03-20 | Seek Thermal, Inc. | Time based offset correction for imaging systems and adaptive calibration control |
US20170285049A1 (en) | 2014-09-01 | 2017-10-05 | Metanomics Gmbh | Means and Methods for Diagnosing Heart Failure in a Subject |
US10182195B2 (en) | 2014-09-23 | 2019-01-15 | Flir Systems, Inc. | Protective window for an infrared sensor array |
US10230909B2 (en) | 2014-09-23 | 2019-03-12 | Flir Systems, Inc. | Modular split-processing infrared imaging system |
US20170322225A1 (en) | 2014-10-22 | 2017-11-09 | Hoffmann-La Roche Inc. | Biomarkers and methods of prediction |
US10557858B2 (en) | 2014-10-29 | 2020-02-11 | Roche Diagnostics Operations, Inc. | Biomarkers for risk prediction of mortality |
US20190359300A1 (en) | 2014-12-31 | 2019-11-28 | FLIR Belgium BVBA | Perimeter ranging sensor systems and methods |
US20160199022A1 (en) | 2015-01-13 | 2016-07-14 | Samsung Medison Co., Ltd. | Ultrasound diagnosis apparatus and method of operating the same |
US9842390B2 (en) | 2015-02-06 | 2017-12-12 | International Business Machines Corporation | Automatic ground truth generation for medical image collections |
US9984283B2 (en) | 2015-02-14 | 2018-05-29 | The Trustees Of The University Of Pennsylvania | Methods, systems, and computer readable media for automated detection of abnormalities in medical images |
US10425603B2 (en) | 2015-03-06 | 2019-09-24 | Flir Systems, Inc. | Anomalous pixel detection |
US11012648B2 (en) | 2015-03-06 | 2021-05-18 | Flir Systems, Inc. | Anomalous pixel detection |
US20180119222A1 (en) | 2015-05-08 | 2018-05-03 | Agency For Science, Technology And Research | Method for diagnosis and prognosis of chronic heart failure |
US20180125820A1 (en) | 2015-05-11 | 2018-05-10 | Novartis Ag | Sacubitril-valsartan dosage regimen for treating heart failure |
WO2017009812A1 (en) | 2015-07-15 | 2017-01-19 | Oxford University Innovation Limited | System and method for structures detection and multi-class image categorization in medical imaging |
US20180265923A1 (en) | 2015-09-15 | 2018-09-20 | Luxembourg Institute Of Health (Lih) | Biomarkers for Heart Failure |
US10623667B2 (en) | 2015-09-18 | 2020-04-14 | Flir Systems, Inc. | High dynamic range radiometric thermal video over low bitrate interface |
US11029211B2 (en) | 2015-12-09 | 2021-06-08 | Flir Systems, Inc. | Unmanned aerial system based thermal imaging systems and methods |
US20180283953A1 (en) | 2015-12-09 | 2018-10-04 | Flir Systems, Inc. | Unmanned aerial system based thermal imaging and aggregation systems and methods |
US20180266886A1 (en) | 2015-12-09 | 2018-09-20 | Flir Systems, Inc. | Airborne inspection systems and methods |
US20190011463A1 (en) | 2015-12-28 | 2019-01-10 | Upstream Medical Technologies Limited | Diagnosis of unstable angina |
US10803553B2 (en) | 2016-01-08 | 2020-10-13 | Flir Systems, Inc. | Systems and methods for image resolution enhancement |
US20180330474A1 (en) | 2016-01-16 | 2018-11-15 | Flir Systems, Inc. | Systems and methods for image super-resolution using iterative collaborative filtering |
US20190064191A1 (en) | 2016-02-04 | 2019-02-28 | Metanomics Gmbh | Means and methods for differentiating between heart failure and pulmonary disease in a subject |
WO2017181288A1 (en) | 2016-04-21 | 2017-10-26 | The University Of British Columbia | Echocardiographic image analysis |
US10143390B2 (en) * | 2016-05-02 | 2018-12-04 | Pie Medical Imaging B.V. | Method and apparatus to automatically determine the relationship between data |
WO2017205836A1 (en) | 2016-05-26 | 2017-11-30 | Icahn School Of Medicine At Mount Sinai | Systems and methods for categorization |
US20190298303A1 (en) | 2016-06-17 | 2019-10-03 | Koninklijke Philips N.V. | System and method for determining hemodynamic parameters of a patient |
US10986338B2 (en) | 2016-06-24 | 2021-04-20 | Flir Systems, Inc. | Thermal-image based video compression systems and methods |
US10937140B2 (en) | 2016-09-29 | 2021-03-02 | Flir Systems, Inc. | Fail-safe detection using thermal imaging analytics |
US20180107787A1 (en) * | 2016-10-17 | 2018-04-19 | International Business Machines Corporation | Workflow for automatic measurement of doppler pipeline |
US20180108125A1 (en) * | 2016-10-17 | 2018-04-19 | International Business Machines Corporation | Automatic detection of disease from analysis of echocardiographer findings in echocardiogram videos |
US20180107801A1 (en) * | 2016-10-17 | 2018-04-19 | International Business Machines Corporation | Automatic disease detection from unstructured textual reports |
US20180103931A1 (en) * | 2016-10-17 | 2018-04-19 | International Business Machines Corporation | Detection of valve disease from analysis of doppler waveforms exploiting the echocardiography annotations |
US20180103914A1 (en) | 2016-10-17 | 2018-04-19 | International Business Machines Corporation | Automatic extraction of disease-specific features from doppler images |
US11010878B2 (en) | 2016-11-04 | 2021-05-18 | Flir Systems, Inc. | Dynamic range compression for thermal video |
US20190325566A1 (en) | 2017-01-03 | 2019-10-24 | FUR Systems, Inc. | Image noise reduction using spectral transforms |
US20200090308A1 (en) | 2017-01-03 | 2020-03-19 | Flir Systems, Inc. | Image noise reduction using spectral transforms |
US20180204364A1 (en) | 2017-01-13 | 2018-07-19 | Flir Systems, Inc. | High visibility overlay systems and methods |
US20200193652A1 (en) | 2017-01-13 | 2020-06-18 | Flir Systems, Inc. | High visibility overlay systems and methods |
US20190335118A1 (en) | 2017-01-13 | 2019-10-31 | Flir Systems, Inc. | Pixel readout with partitioned analog-to-digital conversion systems and methods |
US20190342480A1 (en) | 2017-01-26 | 2019-11-07 | Flir Systems, Inc. | Infrared imaging in multiple imaging modes systems and methods |
US20190369117A1 (en) | 2017-02-13 | 2019-12-05 | Roche Diagnostics Operations, Inc. | Antibodies recognizing generic variants |
US10909660B2 (en) | 2017-02-15 | 2021-02-02 | Flir Systems, Inc. | Systems and methods for efficient enhanced image filtering by collaborative sharpening in similarity domain |
US10598550B2 (en) | 2017-02-17 | 2020-03-24 | Flir Systems, Inc. | Radiometric correction and alignment techniques for thermal imager with non-contact temperature sensor |
US20200005440A1 (en) | 2017-03-15 | 2020-01-02 | Flir Systems, Inc. | Systems and methods for reducing low-frequency non-uniformity in images |
US20200141807A1 (en) | 2017-06-03 | 2020-05-07 | Flir Systems, Inc. | Extensible architecture for surveillance and targetng imaging systems and methods |
US20200401143A1 (en) | 2017-06-16 | 2020-12-24 | FLIR Belgium BVBA | Ultrasonic perimeter ranging sensor systems and methods |
US10986288B2 (en) | 2017-07-27 | 2021-04-20 | Flir Systems, Inc. | Flat field correction systems and methods for infrared cameras |
US20200397313A1 (en) * | 2017-10-06 | 2020-12-24 | Mayo Foundation For Medical Education And Research | Ecg-based cardiac ejection-fraction screening |
US20210219922A1 (en) * | 2017-11-02 | 2021-07-22 | Koninklijke Philips N.V. | A method and apparatus for analysing echocardiograms |
US10983206B2 (en) | 2017-11-07 | 2021-04-20 | FLIR Belgium BVBA | Low cost high precision GNSS systems and methods |
US20190187154A1 (en) | 2017-12-15 | 2019-06-20 | Jana Care, Inc. | Biomedical measuring devices, systems, and methods for measuring peptide concentration to monitor a condition |
US10962420B2 (en) | 2017-12-29 | 2021-03-30 | Flir Systems, Inc. | Pulse detection and imaging systems and methods |
US20200327646A1 (en) | 2017-12-29 | 2020-10-15 | Flir Systems, Inc. | Point cloud denoising systems and methods |
US20210219944A1 (en) * | 2018-05-31 | 2021-07-22 | Mayo Foundation For Medical Education And Research | Systems and Media for Automatically Diagnosing Thyroid Nodules |
US20190392944A1 (en) * | 2018-06-22 | 2019-12-26 | General Electric Company | Method and workstations for a diagnostic support system |
US20200107818A1 (en) * | 2018-10-08 | 2020-04-09 | General Electric Company | Ultrasound cardiac doppler study automation |
US20200113544A1 (en) * | 2018-10-15 | 2020-04-16 | General Electric Company | Method and system for enhanced visualization of ultrasound probe positioning feedback |
US20200178940A1 (en) * | 2018-12-11 | 2020-06-11 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2d and doppler modality echocardiogram images for automated cardiac measurements and the diagnosis, prediction and prognosis of heart disease |
US20200226757A1 (en) * | 2018-12-11 | 2020-07-16 | Eko.Ai Pte. Ltd. | Training neural networks of an automatic clinical workflow that recognizes and analyzes 2d and doppler modality echocardiogram images |
US10702247B2 (en) | 2018-12-11 | 2020-07-07 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and the diagnosis, prediction and prognosis of heart disease |
WO2020121014A1 (en) | 2018-12-11 | 2020-06-18 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2d and doppler modality echocardiogram images for automatic cardiac measurements and the diagnosis, prediction and prognosis of heart disease |
US20200185084A1 (en) * | 2018-12-11 | 2020-06-11 | International Business Machines Corporation | Automated Normality Scoring of Echocardiograms |
US10631828B1 (en) * | 2018-12-11 | 2020-04-28 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and the diagnosis, prediction and prognosis of heart disease |
US20210052252A1 (en) * | 2018-12-11 | 2021-02-25 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and ai recognition of 2d and doppler modality echocardiogram images |
US20210259664A1 (en) * | 2018-12-11 | 2021-08-26 | Eko.Ai Pte. Ltd. | Artificial intelligence (ai) recognition of echocardiogram images to enhance a mobile ultrasound device |
US20210264238A1 (en) * | 2018-12-11 | 2021-08-26 | Eko.Ai Pte. Ltd. | Artificial intelligence (ai)-based guidance for an ultrasound device to improve capture of echo image views |
US11301996B2 (en) * | 2018-12-11 | 2022-04-12 | Eko.Ai Pte. Ltd. | Training neural networks of an automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images |
US11446009B2 (en) * | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
US20210080260A1 (en) | 2019-09-16 | 2021-03-18 | FLIR Belgium BVBA | Imaging for navigation systems and methods |
US20230221878A1 (en) * | 2020-12-31 | 2023-07-13 | Pure Storage, Inc. | Selectable Write Paths With Different Formatted Data |
Non-Patent Citations (6)
Title |
---|
Extended European Search Report for EP Application No. 18943293.3 dated Jul. 6, 2022; 9 pages. |
Madani et al., "Deep echocardiography: data-efficient supervised and semi-supervised deep learning towards automated diagnosis of cardiac disease" NPJ Digital Medicine, vol. 1, No. 1, Oct. 18, 2018. Retrieved from the Internet: <https://www.nature.com/articles/s41746-018-0065-x.pdf>. |
Patent Cooperation Treaty: International Search Report and Written Opinion for PCT/IB2018/001591 dated Sep. 9, 2019; 7 pages. |
Zhang et al., "A Computer Vision Pipeline for Automated Determination of Cardiac Structure and Function and Detection of Disease by Two-Dimensional Echocardiography" dated Jan. 12, 2018; 32 pages; retrieved from the Internet at <https://www.arxiv-vanity.com/papers/1706/07342/>. |
Zhang et al., "Fully Automated Echocardiogram Interpretation in Clinical Practice: Feasibility and Diagnostic Accuracy" Circulation, vol. 138, No. 16, Oct. 16, 2018, pp. 1623-1635. |
Zhang, et al., "Supplemental Material Supplemental Methods for XP055689434: Fully Automated Echocardiogram Interpretation in Clinical Practice: Feasibility and Diagnostic Accuracy", Circulation, American Heart Association, US, Oct. 16, 2018. Retrieved from the Internet Jun. 24, 2022. |
Also Published As
Publication number | Publication date |
---|---|
US20210264238A1 (en) | 2021-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11931207B2 (en) | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device | |
US11446009B2 (en) | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images | |
US10702247B2 (en) | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and the diagnosis, prediction and prognosis of heart disease | |
US11301996B2 (en) | Training neural networks of an automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images | |
US12001939B2 (en) | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views | |
US10930386B2 (en) | Automated normality scoring of echocardiograms | |
Kusunose et al. | A deep learning approach for assessment of regional wall motion abnormality from echocardiographic images | |
US11950961B2 (en) | Automated cardiac function assessment by echocardiography | |
Zhang et al. | Fully automated echocardiogram interpretation in clinical practice: feasibility and diagnostic accuracy | |
Tsang et al. | Transthoracic 3D echocardiographic left heart chamber quantification using an automated adaptive analytics algorithm | |
CN111511287B (en) | Automatic extraction of echocardiographic measurements from medical images | |
US20190392944A1 (en) | Method and workstations for a diagnostic support system | |
US20190139642A1 (en) | System and methods for medical image analysis and reporting | |
US20230351593A1 (en) | Automatic clinical workflow that recognizes and analyzes 2d and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity | |
US20230404541A1 (en) | Method and system for managing ultrasound operations using machine learning and/or non-gui interactions | |
US20240257967A1 (en) | Methods, systems, apparatuses, and devices for facilitating a diagnosis of pathologies using a machine learning model | |
Nova et al. | Automated image segmentation for cardiac septal defects based on contour region with convolutional neural networks: A preliminary study | |
Attaripour Esfahani et al. | A Comprehensive Review of Artificial Intelligence (AI) Applications in Pulmonary Hypertension (PH) | |
Ragnarsdottir et al. | Interpretable prediction of pulmonary hypertension in newborns using echocardiograms | |
US11786212B1 (en) | Echocardiogram classification with machine learning | |
US20240374234A1 (en) | Automatic clinical workflow that recognizes and analyzes 2d and doppler modality echocardiogram images for automated cardiac measurements and grading of mitral valve and tricuspid valve regurgitation severity | |
Jevsikov et al. | Automated mitral inflow Doppler peak velocity measurement using deep learning | |
US20230326604A1 (en) | Automatic clinical workflow that recognizes and analyzes 2d and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy | |
Zolgharni et al. | Automated assessment of echocardiographic image quality using deep convolutional neural networks | |
US20250120676A1 (en) | Echocardiography Deep Learning and Cardiovascular Outcomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: EKO.AI PTE. LTD., SINGAPORE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HARE, JAMES OTIS, II;LAM, SU PING CAROLYN;HUMMEL, YORAN;AND OTHERS;SIGNING DATES FROM 20210331 TO 20210401;REEL/FRAME:055797/0745 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED Free format text: AWAITING TC RESP, ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |